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Cytomegalovirus (CMV) is an important antenatal infection that is prevalent in the developing 
world. The disabling and potentially fatal effects of CMV acquisition or reactivation during 
pregnancy on the developing foetus and or neonate are known but, factors predisposing 
pregnant women to CMV are not well studied. CMV has a wide host cell tropism that includes 
gut epithelial cells. CMV infection in the gut epithelial cells results in a leaky gut and potential 
gut microbial dysbiosis. In this study, we set out to determine the prevalence of CMV infection 
as well as factors associated with CMV reactivation in a cohort of pregnant Zimbabwean 
women. We also aimed to determine the role of CMV infection and CMV susceptibility host 
genetics on gut bacterial profiles. 
Seroprevalence of CMV was determined using the enzyme-linked immunosorbent assay. A 
high prevalence of previous exposure to CMV, as denoted by the presence of anti-CMV IgG 
antibodies in participants’ sera, was observed. Anti-CMV IgM antibodies that denote active 
CMV infection were detected in the sera of 4.6% (n=35/524) study participants. Prevalence of 
CMV was also determined using real time PCR, CMV reactivation was higher (6.7%) when 
using PCR than when using immunological assays (4.6%). The presence of CMV DNA was 
significantly associated with HIV positivity (p=0.04). PCR is the gold standard for CMV 
diagnosis, thus, CMV DNA positivity was used to denote CMV infection status in this thesis. 
The second objective was to determine if the differential effect of CMV acquisition or 
reactivation among HIV infected participants was due to variability in plasma efavirenz 
containing antiretroviral therapy (ART) exposure. Efavirenz (EFV) plasma concentrations were 
determined using high performance liquid chromatography (HPLC). Single nucleotide 
polymorphisms (SNPs) in the CYP2B6 gene, which encodes the main EFV metabolizing 
enzyme were genotyped. Carriers of CYP2B6 poor metaboliser (PM) genotypes (c.516T/T and 
c.983T/C) had significantly higher mean plasma EFV concentration compared to carriers of 
CYP2B6 fast metabolizer genotypes (i.e., c.516G/G and c.983T/T). CYP2B6 PM genotype 
carriers were significantly less likely to be positive for CMV DNA when compared with fast 
metabolizer genotype carriers (p<0.001 for both SNPs).  
Considering the role of the immune system in keeping latent CMV infection in check, the third 
objective was to determine the role of SNPs in genes coding for proteins involved in response 
against CMV. Twenty SNPs in 10 genes (TLR2, TLR4, TLR7, TLR9, IL6, IL6R, IL10, IL28B, 
IFNAR1, IL1A) were characterized and the following were found to be significantly associated 
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with increased risk of CMV infection; TLR2 rs1816702T>C (p=0.002), TLR7 rs179008A>C 
(p<0.001), TLR9 rs352139T>C (p=0.003).  In contrast, presence of the IL6 rs10499563T>C 
polymorphism was inversely correlated with CMV infection (p=0.002). The reported genetic 
variants are reported to modulate proteins involved in immune responses against viral 
infections, thus, their association with susceptibility to CMV infection. Such findings may 
assist in the designing of a much-needed candidate CMV vaccine.   
Lastly, we set out to determine the possible role of CMV infection in shaping gut microbiota 
profiles. We report on a significant difference (p=0.001) in the beta diversity of gut bacterial 
profiles between HIV- and age-matched CMV-infected (cases) and CMV-uninfected (controls) 
participants.  Using linear discriminant analysis (LDA) effect size (LefSe), significant 
differences in the relative abundance of specific bacterial taxa were observed between cases 
and controls (p<0.05, LDA>2). Significantly lower abundance of Lactobacillus reuteri and 
Roseburia, genera associated with lower microbial translocation was observed in cases than 
controls. Lower relative abundance of Lactobacillus and Roseburia, is consistent with 
microbial translocation and heightened inflammation, respectively, hence higher likelihood of 
microbial translocation and inflammation occurring in cases than controls. Furthermore, 
Prevotella copri, a species that has been association with cytokine release and chronic 
inflammation was significantly more abundant in cases than controls. CMV is a known chronic 
inflammatory condition, and this study provides further confirmation through the higher 
relative abundance of P.copri in cases than controls. Biomarker identification has proven to be 
a successful means of translating molecular data into clinical practice, such as vaccine 
development in the case of CMV infection. 
Overall, this study reports the possible interaction of various host factors in facilitating CMV 
acquisition or reactivation during pregnancy. In the setting of HIV-CMV coinfection, our 
findings emphasise on the need for genotype guided drug dosage to achieve therapeutic EFV so 
as to maintain the balance between host and coinfecting microbes in HIV management. 
Comprehensive genotype guided drug dosage, if taken as a once-off test should be affordable 
especially in resource-limited settings. This is particularly important in pregnant women who 
are at a risk of vertically transmitting infection to the immunologically immature foetus and or 
neonate. Data from this study may assist in curbing the host associated challenges in designing 
an effective CMV vaccine. Moreover, the biomarkers reported may assist in diagnosis and 
management of potential CMV acquisition or reactivation during pregnancy.  However, bigger 
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prospective, functional studies would be needed to confirm the exact roles of the biomarkers 
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1 Chapter 1: Introduction and Literature Review 
 
Synopsis  
Chapter 1 consists of three parts which are as follows:  
(i) An overview of the global prevalence, structure, life cycle, pathophysiology, immunity 
elicited, as well as treatment of cytomegalovirus (CMV), from section 1.1 to section 1.5 
 
(ii) A published review on the epidemiology of CMV infection among pregnant women in 
Africa. The review was published in the Journal of Infection in Developing Countries 
(available here; https://jidc.org/index.php/journal/article/view/11373/2135). This part makes 
up section 1.6 
 
(iii) This final section (section 1.7 to 1.7.2) of chapter 1 provides the aims, rationale to the 
concept and the specific objectives that were developed and executed in order to address the 
thesis aims. 
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1.1 Overview and Background  
Cytomegalovirus (CMV) is a common infection which is almost ubiquitous in the developing 
world. CMV infection may occur in people without prior exposure to the virus, resulting in 
primary infection and may also reactivate in those with latent infection or may be reinfected 
with a different strain of CMV (Itell, Nelson, Martinez, & Permar, 2017). All three instances 
CMV infection usually remain asymptomatic and subclinical, mainly because the immune 
system keeps viral replication under control. However, in patients who fail to mount adequate 
immunity, CMV may be uncontrolled and lead to high viral loads which are associated with 
viral shedding, dissemination to multiple organs and diseases such as pneumonitis, retinitis, 
hepatitis or gastroenteritis (Emery, 2001; Zuhair et al., 2019). CMV therefore becomes an 
important pathogen in individuals with immature or compromised immunity such as the 
unborn child, pregnant women, HIV infected and allograft recipients. CMV may have 
potentially fatal effects in the setting of compromised or immature immunity.  
When any of the three types of CMV infections occur in pregnancy, an antenatal infection 
results which can potentially be transmitted to the developing foetus, during parturition and 
within the first 21 days post-natal, resulting in congenital CMV infection (cCMV) (Pass & 
Anderson, 2014). In the ART era, which has resulted in a massive decrease in vertical 
transmission of HIV, cCMV has become the most common vertically transmitted pathogen, 
impacting approximately one million newborns annually, globally (Dollard, Grosse, & Ross, 
2007; Kenneson & Cannon, 2007). cCMV can occur as a result of any of the three types of 
CMV infection in pregnancy, with viraemia leading to involvement of the placenta then the 
foetus. cCMV has resulted in a global burden of permanent sequelae such as sensorineural 
hearing loss, growth restriction and intellectual disability (Lanzieri et al., 2017). Moreover, 
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cCMV has recently been linked to an increased risk of lymphoblastic leukemia and chronic 
conditions such as glioblastoma (Francis et al., 2017).  
This thesis is focused on the prevalence of CMV factors that may be associated with 
acquisition of CMV during pregnancy.  
1.2 Global burden of CMV 
CMV infection is transmitted from person to person through contact with infectious mucosal 
body fluids such as blood, urine, saliva, breast milk, genital secretions and blood products. 
CMV is also transmitted during solid organ transplantation or intrauterine from mother to 
foetus during pregnancy (Forbes, 1989; Numazaki, Chiba, & Asanuma, 2001). As a result, 
CMV is one of the most successful human pathogens as it can be transmitted both 
horizontally and vertically. CMV infection status is generally determined by detection of anti-
CMV immunoglobulin G (IgG) and immunoglobulin M (IgM) in serum. Detection of CMV 
DNA by polymerase chain reaction (PCR), the gold standard is a more reliable method and 
gives a better reflection of the presence of the virus. However, routine diagnosis of CMV is 
done by detection of anti-CMV antibodies as it is a more accessible method. 
Globally, between 40 and over 90% of the general population are infected with CMV, with 
prevalence increasing as we move from developed to developing world (Zuhair et al., 2019). 
In the developed world, seroprevalence ranges from 40-70% and tends to increase with 
increasing age (Cannon & Davis, 2005; Zuhair et al., 2019). In the developing world, most 
seroconversion occurs during childhood, resulting in adult seroprevalence of 80 to over 90% 
(Cannon & Davis, 2005). Similarly, seroprevalence of CMV in women of child bearing age 
follows the same trend, with higher rates in the developing world compared to the developed 
world, as shown in Figure 1.1.   
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The epidemiology of maternal CMV has a complex relationship with that of cCMV since 
maternal infection sustains cCMV. The vertical transmission rates of CMV are 1-5% and 0.6-
0.7% in high seroprevalence and low prevalence settings, respectively (Dollard et al., 2007; 
Kenneson & Cannon, 2007). The global mortality rate of cCMV is approximately 30% 
(Zuhair et al., 2019). However, a considerable number of cCMV are likely missed due to the 
asymptomatic nature of cCMV. Significant differences in seroprevalence exist between 
populations, which correlate closely to socioeconomic status, race and variations in burden of 
immunodeficiency diseases, among other factors.  
 
Figure 1.1. Global CMV seroprevalence rates in women of child bearing age (Adapted from 
Zuhair et al., 2019) 
 
1.3 CMV structure, life cycle and pathogenesis 
Cytomegalovirus (CMV) is a member of the human herpesvirus family that consists of 8 
viruses: herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), varicella-zoster 
virus (VZV), Epstein-Barr virus (EBV), CMV, human herpes virus 6 A and B (HHV-6A and 
B), human herpes virus 7 (HHV-7), and human herpes virus 8 (HHV-8) (McGeoch, Cook, 
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Dolan, Jamieson, & Telford, 1995). The Herpesviridae family can be divided into three 
subfamilies (herpesvirinae): alpha, beta and gamma. CMV belongs to the beta (β) family of 
herpesviruses, which infect organisms in a species-specific manner (McGeoch et al., 1995; 
Tomtishen III, 2012). 
CMV is a typical herpes virion which is approximately 200-300nm in diameter and contains 
three identifiable regions, the capsid 100nm in diameter embedded in a proteinaceous matrix 
(the tegument), which is surrounded by a lipid envelope (Shenk & Stinski, 2008)(Figure 1.2). 
The capsid exhibits icosahedral symmetry with 162 capsomers enclosing the large double 
stranded DNA genome (Chen, Jiang, Lee, Liu, & Zhou, 1999; Shenk & Stinski, 2008). CMV 
represents the largest genome of the characterised human herpesvirus family to date, with a 
genome of 236 kbp (Cha et al., 1996; Riley, 1997; Stern-Ginossar et al., 2012). The CMV 
genome is estimated to contain ~192 open reading frames encoding more than 80 viral 
proteins, including glycoproteins which are located in the tegument  (Cha et al., 1996; Chee et 
al., 1990; Gibson, 2008). These include glycoprotein B (gB), gH, gL, gM, gN and gO which  
serves various functions including adsorption to host cells (Varnum et al., 2004). The genome 
is packaged in an icosahedral capsid surrounded by a lipid envelope. Viral phosphoproteins 




Figure 1.2. CMV virion structure and structural components 
(https://pedclerk.bsd.uchicago.edu/page/cytomegalovirus-cmv). 
 
CMV effectively penetrates virtually all types of cells, including epithelial cells of gland and 
mucosal tissue, smooth muscle cells, fibroblasts, macrophages, dendritic cells, neurons, 
hepatocytes and vascular endothelial cells (Sinzger, Digel, & Jahn, 2008). This penetration 
occurs through endocytosis and fusion at low-pH in epithelial and endothelial cells while it is 
accomplished by a pH-independent fusion (Ryckman, Jarvis, Drummond, Nelson, & Johnson, 
2006). The receptor-mediated endocytosis is triggered by virally encoded glycoproteins 
particularly gB and gH, binding to target cellular receptors (Vanarsdall & Johnson, 2012). As 
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the virus penetrates the cell, viral proteins regulate cell-signaling pathways and cellular 
metabolism to support viral replication and immune evasion. 
After membrane fusion, the viral capsid loses its tegument layer (Feng, Schröer, Yu, & Shenk, 
2006). The released tegument proteins facilitate the migration of the viral capsid towards the 
nucleus, via microtubules, the release of the viral genome from the capsid, and activation of 
viral gene expression (Compton & Feire, 2007). Viral genome replication can now occur in 
the new host cell. Once within the nucleus the viral DNA genome circularises by fusion of 
double stranded DNA termini. The circular DNA becomes a template for DNA replication 
forming large interlinked DNA copies. After circularisation, a tegument protein and cell 
proteins bind to DNA in order to initiate transcription signaling CMV lytic infection which is 
characterised by a finely-regulated cascade of gene expression separated into: (i) immediate 
early (IE) genes that encode proteins responsible for initiating and terminating each of the 
subsequent steps in replication. (ii) early (E) encode proteins that are responsible for viral 
DNA replication. Both IE and E proteins contribute to a cellular environment which is 
optimal for viral gene expression and viral genome synthesis (Fields, Knipe, & Howley, 2007; 
Fortunato & Spector, 1999). Late (L) genes encode viral structural proteins responsible for 
virion assembly and maturation. Late genes are expressed from around 48 hours post 
infection, and their expression begins the production of infectious virions (Fields et al., 2007).  
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Figure 1.3. Overview of the CMV life cycle (Crough & Khanna, 2009). 
 
In the late stages of replication, the capsid is assembled in the nucleus. Nucleocapsid particles 
accumulate in inclusions that represent one of the cytopathic effects of CMV infected cells 
(intracellular inclusions) (Griffiths, Baraniak, & Reeves, 2015). CMV associated diseases 
occur when the immune system loses control of either primary or reactivated viral infection. 
During the lytic cycle, viral replication disrupts the cytoskeleton, causing massive cell 
enlargement (Griffiths et al., 2015; Klemola, Von Essen, Henle, & Henle, 1970). The 
replication continues for several days until cell lysis occurs. The wide cell tropism of CMV 
has resulted in CMV being implicated in multiple organ-specific damages such as CMV 
colitis, hepatitis, pneumonitis, retinitis (Sinzger & Jahn, 1996). Viral replication and load are 
important factors in pathogenesis, with CMV viral load being directly associated with disease 
(Cope et al., 1997; McBride et al., 2019; Regoes et al., 2006). A threshold relationship 
between CMV viraemia and disease has been described in renal and liver transplant patients 
where the quantity of CMV in serum was directly linked to the risk of CMV recurrence, 
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pathogenicity and mortality (Humar, Kumar, Boivin, & Caliendo, 2002; McBride et al., 
2019).  
CMV infected immunocompromised patients present with protracted fever, fatigue or malaise 
and  increased white blood cell count (Britt, 2008). Immunocompetent hosts are usually 
asymptomatic but may present with a self-resolving mononucleosis syndrome. CMV can also 
cause organ specific damage such as CMV colitis, granulomatous hepatitis and focal 
neurological deficits (Poole, Wills, & Sinclair, 2014). cCMV infection has been associated 
with cerebral calcifications which result in neural and developmental disorders (Cheeran, 
Lokensgard, & Schleiss, 2009).  
1.4 Immune response to CMV infection 
The outcome of viral infections is determined by tropism and virulence of the virus, its ability 
to manipulate the immune system, and, notably, the effectiveness of the host's immune 
response in retaining the virus. Relationship between CMV and host immunity, including 
recognition, priming, and the subsequent host response, is a major determinant of CMV 
pathogenesis. CMV infection triggers forceful immune reaction in the human body, initially 
by innate natural killer (NK) cells, followed by adaptive CD4+ and CD8+ T cells and B cell 
high avidity neutralizing antibodies (Rook, 1988). Figure 1.4 illustrates the different types of 




Figure 1.4. Immunity against CMV (https://www.immunology.org/public-
information/bitesized-immunology/pathogens-and-disease/human-cytomegalovirus-hcmv) 
 
1.4.1 Innate immunity 
The innate immunity is normally the first line of cellular defense, which afterwards has a 
cross interaction priming the adaptive immunity response. Innate immunity does not confer 
long term immunity against pathogens but it is the dominant immune system of host defense 
 11 
in initial response, hence plays a big role in determination of the strength of subsequent 
immune responses (La Rosa & Diamond, 2012). The innate immunity relies on evolutionarily 
ancient germ line encoded receptors, pattern-recognition receptors (PRRs) that recognize 
highly conserved microbial molecular structures, known as pathogen associated molecular 
patterns (PAMPs). The PRRs that play a role in immunity against CMV are the toll like 
receptors (TLRs) (Compton et al., 2003).  
TLRs are generally expressed on almost all the immune effector cells; macrophages, mast 
cells, neutrophils, dendritic cells, basophils, eosinophils and natural killer cells (Botos, Segal, 
& Davies, 2011). Attachment and binding of viral glycoproteins, particularly gB and gH to 
host-cell toll-like receptors (TLR) activate transcription factors, which are the first defense 
mechanism of the host cell (e.g. nuclear factor kappa (NFκ-B) (Boehme, Guerrero, & 
Compton, 2006; Powers, DeFilippis, Malouli, & Früh, 2008). These factors induce 
inflammatory cytokines and interferon-stimulated genes, such as tumor necrosis factor (TNF-
α), interleukin (IL)-1, IL-6, IL-8, IL12 and IL-18 to inhibit viral replication and initiate 
adaptive immune responses (Kogut, Chiang, Swaggerty, Pevzner, & Zhou, 2012; La Rosa & 
Diamond, 2012).  
1.4.2 Adaptive immune response 
Adaptive immune response is closely related to the innate immune response and the pathway 
of communication is one target of HCMV evasion. Adaptive immunity is classified into 
humoral and cellular immunity. Humoral immunity is mediated by B-lymphocytes, which 
secrete antibodies. Antibodies are produced to target viral phosphoproteins and glycoproteins. 
HCMV specific antibodies have neutralizing activity and complement fixing activity that is 
important to disrupt viral replication (Gerna et al., 2008; Macagno et al., 2010). T-
lymphocytes mediate cellular immunity, and consist of CD8+ cytotoxic T cells and CD4+ 
helper T cells. CD8+ T cells are able to recognise and destroy infected cells via recognition of 
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viral peptides presented via MHC-I molecules on infected cell surface while CD4+ helper T 
cells are mediated by expression of MHC-II molecules (Hertoghs et al., 2010; Sylwester et al., 
2005).  
The capacity of CMV to establish latency and to co-exist with the host may be the result of 
multiple immune evasion strategies. The large genome of CMV codes for various proteins 
which aid in immune evasion thereby facilitating latency and co-evolution with the human 
host, following a primary infection. Viral proteins such as UL16 and UL18 are responsible for 
helping the virus to avoid apoptotic signaling and NK response (Jackson, Mason, & Wills, 
2011; Noriega, Redmann, Gardner, & Tortorella, 2012). CMV has also been shown to 
downregulate both MHC class I and II expression in infected cells and to interfere with MHC 
class II expression by several mechanisms (Jackson et al., 2011; Tortorella, Gewurz, Furman, 
Schust, & Ploegh, 2000). 
1.5 Treatment and vaccine against CMV 
1.5.1 Antiviral treatment 
Several anti-viral drugs such as ganciclovir, valganciclovir, foscarnet and cidofovir are 
available for the treatment of CMV. Ganciclovir and its prodrug valganciclovir are nucleoside 
analogues which inhibit viral DNA polymerase are the currently approved drugs for first line 
treatment of CMV (Freitas, Smee, Chernow, Boehme, & Matthews, 1985; Martin, Dvorak, 
Smee, Matthews, & Verheyden, 1983). In addition to reported viral resistance after a few 
months of therapy, ganciclovir has been associated with neutropenia, thrombocytopenia and 
putative long term infertility (Faqi, Klug, Merker, & Chahoud, 1997; Steininger, 2007). 
Valganciclovir has therefore become a drug of choice for cCMV disease (Kimberlin et al., 
2015). The second-line regimen for CMV treatment comprises DNA polymerase inhibitors 
foscarnet and cidofovir, UL97 kinase inhibitor maribavir and nucleocapsid tegumentation 
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inhibitor leflunomide (Chacko & John, 2012; Tan, 2014). Letermovir, a viral terminase 
inhibitor is used to prevent infection and disease in CMV seropositive patients (Foolad, 
Aitken, & Chemaly, 2018; Verghese & Schleiss, 2013). None of the CMV treatment drugs are 
licensed for use during pregnancy as cidofovir and foscarnet are nephrotoxic and likely to 
have teratogenic effects on the foetus. Ganciclovir has been shown to affect development of 
sexual organs in animal studies (Rawlinson et al., 2017; Tan, 2014) and similar results are 
anticipated for a developing foetus, hence ganciclovir use during pregnancy is prohibited. 
Safety of use during pregnancy has not been assessed in the other CMV treatment drugs. 
Furthermore, the high costs of anti-CMV drugs are inhibiting and makes CMV treatment 
highly inaccessible in the developing world.   
The Food and Drug Administration of the USA has also approved CMV human 
immunoglobulin (HIG) therapy for prophylaxis of CMV infection. CMV HIG is a high titre of 
plasma derived anti-CMV antibodies collected from donors with high antibody levels. For 
prevention of cCMV, CMV HIG has mostly been used as an intervention in cases where 
maternal ante-natal seroconversion has been confirmed. Nigro et al. (Nigro et al., 2012) 
conducted  a nonrandomized clinical trial among women with known recent CMV primary 
infection divided into two groups, one that received CMV HIG and the second group which 
did not receive CMN HIG. After administration of HIG before 21 weeks of gestation, it was 
observed that there was a significant difference in cCMV infection with infants in the HIG 
arm having less infection (16%) compared to 40% in the control group, suggesting a 
protective effect of CMV HIG. However, another study in Italian pregnant women did not 
show any differences (Revello et al., 2014). Findings from clinical trials investigating the 
utility of HIG in treatment of CMV have been inconclusive and unsatisfactory hence, no 
recommendation of HIG in clinical management of CMV to date (Khalil, Jones, & Ville, 
2017). 
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1.5.2 Vaccine against CMV 
Owing to the significant morbidity, mortality and sequelae associated with CMV, the 
American Institute of Medicine has prioritised the development of CMV vaccine (Medicine, 
1999) while the Centre for Disease Control has  assigned it second highest priority after HIV. 
Since then, a potent vaccine for CMV infection has not been found. Over the years, the need 
for CMV vaccine has been overtaken by other viruses such as HIV, HPV and the flu virus. 
However, CMV infection is still a public health challenge especially during pregnancy where 
there is risk of vertical transmission with potentially fatal effects.  
In a clinical trial, a candidate vaccine  which was live attenuated Towne strain of CMV had 
low immunogenicity and was unable to protect against reactivation of infection (Cheeran et 
al., 2009; Plotkin et al., 1994). The ability of CMV to superinfect an already persistently 
infected host complicates the development of an effective vaccine. In addition, considering 
the multi-tier arsenal used by CMV to evade host immune defenses, a vaccine that 
incorporates different viral immunogens which can elicit a robust, adequate immune response 
is needed.  
The first phase II randomized, double blinded, placebo-controlled clinical trial was a 
recombinant CMV gB vaccine and MF59 adjuvant (Pass et al., 2009). The vaccine protected 
50% of seronegative women against primary infection. Trials for CMV vaccine have been 
ongoing but none has shown complete potency against CMV. As a result, there currently is no 





1.6 Epidemiology of Cytomegalovirus among pregnant women in Africa  
Based on published review; Doreen Mhandire, Sarah Rowland-Jones, Kudakwashe Mhandire, 
Mamadou Kaba, Collet Dandara (2019). A review on the epidemiology of Cytomegalovirus 
infection among pregnant women in Africa. Journal of Infection in Developing Countries 13:865-
876. doi: 10.3855/jidc.11373 
Abstract 
Vertical transmission of Cytomegalovirus (CMV), resulting in congenital CMV (cCMV) 
infection could have disabling and potentially fatal effects on the foetus or neonate. Although 
primary infection probably has a higher risk of leading to cCMV, in highly seropositive 
populations, a significant risk of vertical transmission is thought to be due to CMV 
reactivation and or reinfection during pregnancy. In this narrative review, we summarise the 
prevalence of CMV infection and associated risk factors among pregnant African women, in a 
setting where primary CMV infection usually occurs during infancy. A systematic search of 
literature published between January 2000 and January 2019, retrieved on five bibliographic 
databases was performed. Search for relevant articles was performed using the following 
keywords: cytomegalovirus, CMV, infection, antenatal infections, pregnancy, pregnant 
women, gravidity, developing countries and Africa, with appropriate qualifiers such as OR, 
AND. Systematic searching retrieved 11 relevant original research papers. Prevalence of anti-
CMV IgG and IgM antibodies ranged from 60-100% and 0-15.5%, respectively. Prevalence 
of CMV DNA ranged from 0-29%, depending on the specimen used. However, there was no 
geographic trend for CMV seroprevalence or CMV DNA prevalence across the African 
continent. Overall, a substantial percentage of women of reproductive-age were CMV 
seronegative and at risk of primary infection. Association of sociodemographic factors with 
CMV infection were inconsistent across all reviewed studies. The limited data and 
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inconsistency of findings from the few studies carried out in Africa calls for prospective 
studies comparing prevalence and outcomes of cCMV in infants born to women with both 
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Introduction 
Cytomegalovirus (CMV) is the second most 
common cause of congenital viral infections in the 
developing countries, after HIV [1]. Congenital CMV 
(cCMV) occurs when there is transmission of CMV 
from the mother to the infant in utero or perinatally. 
Congenital CMV is diagnosed by the detection of CMV 
DNA in any of the infant’s body fluids within the first 
21 days of life [2]. Because CMV infection or 
reactivation takes advantage of decreased or 
compromised immunity, pregnant women are 
particularly at risk of CMV reactivation due to the 
immune down-regulation which occurs in pregnancy. 
Pregnancy has been described as an immunological 
condition which presents multiple challenges in 
diagnosis, prevention and management of infectious 
diseases [3].  
Maternal immunity acquired against CMV prior to 
conception does not confer complete protection to the 
developing foetus, as is the case with the other antenatal 
and perinatal congenital infections such as 
toxoplasmosis and rubella. As a result, vertical 
transmission of CMV can occur in both primary and 
non-primary maternal infections with rates of 30% and 
2%, respectively [4–5]. It was previously believed that 
vertical transmission of CMV and severe neonatal 
symptoms of cCMV only occur in infants born to 
mothers with primary infection in pregnancy. However, 
over 60% of the infants infected in utero with CMV are 
born to mothers with preconceptional immunity who 
have secondary infection in pregnancy, and more and 
more studies show severe sequelae in these infants. We 
therefore conclude that congenital CMV may be a 
significant problem even in children born to mothers 
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Study selection 
Literature for this review was accessed from 
PubMed/ Medline, Scopus, EBSCOHost, African 
Journals Online (AJOL) and Institute for Scientific 
Information (ISI) web of knowledge databases. The 
search terms were as follows: (cytomegalovirus OR 
CMV OR CMV infection) AND (antenatal infections) 
AND (pregnancy OR pregnant women OR gravidity) 
AND (Africa OR developing countries). The search 
strategy was discussed by all authors, adjusted to ensure 
maximum relevance and read by DM. The identified 
papers were then read by DM and results were recorded 
in Table 1, in which we entered details about the study 
population, method of CMV diagnosis, country and 
province/city of study as well as CMV 
seroprevalence/prevalence. We then compared the 
details of included papers for commonalities. 
 
Results 
The search strategy, summarised in Figure 1 yielded 
78 articles, whose abstracts were all reviewed. Sixty-
four abstracts were excluded for one or more of the 
following reasons: were not carried out in 
Africans/African countries; did not report on 
seroprevalence or prevalence of CMV. Three of the 
remaining 14 full text articles were excluded because 
the studies did not focus on pregnant women. Only full 
text articles published in English were included in this 
review. An article publication date range of January 
2000 to January 2019 was selected to enable a sample 
of studies large enough to inform meaningful 
discussion and recent enough that it reflects current 
practice. We accessed 11 full articles reporting the 
prevalence of CMV in pregnancy in Africa. Of the 11 
studies, two were conducted in North Africa (both in 






DNA (n) IgM % IgG % 
East Africa      
Kenya 260 women at Thika hospital ND 8 77 [36] 
Ethiopia 200 women in Addis Ababa ND 16 89 [35] 
Sudan 231 women in El-Rahad ND 3 72 [37] 
Tanzania 261 women in Mwanza ND 0.4 74 [38] 
North Africa      
Egypt 546 women in Ismailia ND 7 100 [30] 
Egypt 
62 women (50 with a history of recurrent 
spontaneous abortion (cases), 12 with no history 
of spontaneous abortion (controls) in Mansoura) 
12 in cases 
0 in controls 
ND ND [29] 
West Africa      
Ghana 72 women in Jomoro ND 0 100 [32] 
Nigeria 174 women in Osogbo ND  60 [33] 
Gambia 169 HIV-infected women in Sukutu 
Vaginal swab – 24 
Colostrum – 29 
Saliva – 13 
Urine – 1 
Plasma – 2 
 100 [31] 
Nigeria 180 women in Kano ND ND 91 [34] 
Southern 
Africa 
     
Malawi 81 HIV-infected ART-naïve women in Blantyre ND ND 100 [39] 
* - all participants were pregnant and in the reproductive age (18-45 years), ND - not done, DNA – CMV DNA detected in any type of body fluid, IgM – anti-
CMV IgM antibodies detected in serum, IgG – anti-CMV IgG antibodies detected in serum. 
Figure 1. Flow diagram of the article searches yielded, excluded 
and reviewed for the purpose of this review. 
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Egypt [29,30]), four in West Africa (one in each of 
Gambia [31] and Ghana [32], two in Nigeria [33,34]), 
four in East Africa (one in each of the following 
countries; Ethiopia [35], Kenya [36], Sudan [37] and 
Tanzania [38]); and one in Southern Africa (Malawi) 
[39]. 
 
Prevalence of Cytomegalovirus in pregnancy 
All studies reported CMV IgG seroprevalence, with 
five concurrently reporting CMV IgM results. 
Prevalence of anti-CMV IgG seropositivity during 
pregnancy in Africa ranged from 60% to 100%. Four of 
the 11 studies (conducted in Gambia, Egypt, Malawi 
and Ghana) reported 100% CMV IgG seroprevalence, 
demonstrating that the entirety of the study participants 
in these studies had been exposed to CMV in their 
lifetime. This is in keeping with studies in Gambian 
infants which showed that 100% of children acquired 
CMV infection by the age of eighteen months [10]. Two 
of the 11 studies reviewed reported on the prevalence 
of CMV DNA. Table 1 presents an overview of all the 
studies included in this review as well as CMV 
prevalence. 
 
Factors associated with acquisition of CMV in African 
pregnant women 
HIV co-infection 
Two studies from Gambia and Malawi enrolled 
HIV-infected women only. The Kenyan study enrolled 
both HIV-infected and HIV- uninfected women in order 
to investigate HIV as a risk factor for CMV infection in 
Kenyan pregnant women. The Kenyan study reported 
no significant association between HIV status and 
CMV infection [36]. The remaining eight studies did 
not consider HIV as a risk factor for CMV infection or 
did not have data on the HIV status of participants 




None of the reviewed studies considered socio-
economic status as a correlate of CMV acquisition. 
However, several factors can be considered markers of 
socio-economic status, among them, place of residence, 
employment status, income and level of education [40]. 
The study carried out in Kenya reported on a significant 
association between risk of CMV infection and low 
levels of education (Odds ratio (OR) = 3.8, 95% CI = 
3.023–6.96, p < 0.001) [36]. Hamid et al. [34] did not 
find any significant association between occupation and 
CMV seropositivity in Nigerian pregnant women. 
Contrary to findings from the Nigerian study, a study 
among Sudanese women [37], where an association 
between illiteracy and CMV IgG seropositivity (p < 
0.05) was reported. However, the study carried out 
among Sudanese women did not report odds ratios or 
95% confidence intervals. A study done on a Tanzanian 
cohort reported urban residence to be a risk factor for 
CMV IgG seropositivity (OR = 6.329, 95% CI 2.885–
13.887, p < 0.001) [38]. 
 
Maternal age and parity 
Three of the 11 studies in this review investigated 
age as a risk factor for CMV acquisition in pregnancy. 
Zaki and Goda [29] reported a significantly (p < 0.001) 
higher median age among IgG seropositive (median = 
25, IQR 19–27) compared to that of IgG seronegative 
(median = 20, IQR 18–20) Egyptian women. Among 
Tanzanian women, a one-year age increase resulted in 
a 0.3% (95% CI 0.13–0.47, p = 0.001) increase in 
seroprevalence while at the same time the risk of being 
CMV IgG positive increased by 24% [38]. Hamdan et 
al. [37] observed that advanced maternal age was 
associated with a higher risk of CMV seropositivity in 
Sudanese pregnant women. However, the significance 
was lost after multivariate analysis [37], suggesting that 
the influence of maternal age on CMV acquisition could 
perhaps be marginal. Studies done in Kenyan and 
Nigerian women did not report any association between 
maternal age and risk of CMV seropositivity [34,36]. 
Higher parity was found to be significantly associated 
with a higher risk of CMV infection in the studies 
carried out in Tanzanian (OR = 2.9, 95% CI 1.6-5.4, p 
< 0.001), Kenyan (OR = 3.8, 95% CI 3-7, p < 0.0001) 
and Sudanese (OR = 15, 95% CI 2-123, p = 0.01) 
pregnant women [34,36–38]. 
 
Blood transfusion 
Two of the 11 studies investigated history of blood 
transfusion as a risk factor for CMV seropositivity 
[33,36]. There was a significant difference (p < 0.05) in 
CMV IgG seropositivity between women who 
previously had a blood transfusion (93%) compared to 
women without a transfusion history (82%) among 
Nigerian women [34]. This finding was confirmed by 
observations in the Kenyan cohort, where history of 
blood transfusion was associated with both CMV IgG 
and IgM antibody seropositivity [36]. 
 
Recurrent spontaneous abortion 
Four of the 11 studies investigated CMV 
seropositivity as a risk factor for history of recurrent 
spontaneous abortion [29,35,37-38]. CMV 
seropositivity was reported to be significantly 
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associated with history of spontaneous abortion in the 
Tanzanian study, both in univariate (OR = 5.6, 95% CI 
1.3-24.2, p < 0.02) and multivariate analysis (OR = 5.2, 
95% CI 1.1-24.4, p = 0.038) [38]. In addition to a 
significant association between IgG seropositivity and 
history of spontaneous abortion in the Tanzanian 
cohort, the only woman who was CMV IgM 
seropositive had adverse birth outcomes with a low 
birth weight baby who also had microcephaly and spina 
bifida, consistent with a cCMV diagnosis [38]. In 
contrast, Yeshwondm et al. [35], Hamdan et al. [37] as 
well as Zaki and Goda (29) reported no significant 
association between history of spontaneous abortion 
and CMV infection in Ethiopian, Sudanese and 
Egyptian pregnant women, respectively. 
 
Discussion 
Seroprevalence of CMV 
The prevalence of CMV observed in African 
countries is generally higher than the average 40% to 
70% reported in the developed world [41]. The 
seroprevalence estimates reported in all the studies 
reviewed here were obtained using enzyme linked 
immunosorbent assays (ELISA) and therefore can be 
regarded as relatively comparable. Of all the methods 
used to detect presence of antibodies, ELISA has been 
found to be the most superior and reliable [26]. 
However, detection of CMV DNA by polymerase chain 
reaction (PCR), the gold standard for detection of CMV 
in body fluids, provides a better reflection of the 
presence of actively replicating virus. CMV PCR 
compared to immunoglobulin assays offers superior 
specificity (100% vs 96%) and sensitivity (100% vs 
22%) [42]. However, PCR may result in false positives 
for active CMV infection as it can also detect genetic 
material from latent viruses [43]. PCR is a relatively 
expensive assay that requires use of commercial kits 
and specialist equipment; hence, access to the technique 
in the African setting is limited. Thus, serology remains 
the method of choice. As such, seroprevalence is the 
main tool for CMV surveillance on the continent, hence 
forms the main focus of this review. 
Exposure to CMV among African pregnant women 
in the reviewed studies was very high, but appears to 
vary across the continent. The prevalence of active 
infection, denoted by presence of IgM antibodies (0-
15.5%), was much lower than that of IgG antibodies 
(60-100%) [29–39]. However, the seroprevalence of 
both CMV IgG and IgM antibodies did not show any 
geographic trends across the African continent. This 
observation probably rules out a possible role for 
geographical hotspots in CMV acquisition. The 
discrepancy between high CMV IgG seropositivity and 
low CMV IgM seropositivity suggests that the majority 
of the congenital CMV cases in high CMV prevalence 
settings in the reviewed studies are consequent of non-
primary infection [44]. Thus, CMV antibody avidity, an 
additional measurement meant to detect IgG positive 
individuals in whom CMV is likely to have been or is 
reactivated is critical in clinical decision making when 
serology is the only available method of diagnosis.  
Two studies conducted in Egypt and Kenya 
reported avidity results and noticeably there were 
discrepancies between IgM seropositivity and low IgG 
avidity in both studies [30,36]. In the Egyptian study, 
40% tested positive for IgM antibodies, but none of the 
participants that tested positive for CMV IgM 
antibodies had IgG antibodies of low avidity. This 
could suggest that CMV IgM antibodies persist in the 
circulation for longer than 6 weeks and hence may not 
be a good marker of current CMV infection [30]. On the 
other hand, the Kenyan study reported a low avidity IgG 
antibodies prevalence of 5%, which was less than the 
8% seroprevalence of IgM antibodies [36]. Such 
discrepancies between IgM and IgG avidity test 
outcomes highlight some of the challenges faced in 
detection of potentially vertically transmissible CMV 
infections during pregnancy. Despite IgG avidity being 
the readily available method for ascertaining 
recent/current infection in Africa, a previous study in 
Italian women found vertical transmission of CMV to 
be 4% and 2% among women with intermediate and 
high anti-CMV IgG antibody avidity, respectively [45]. 
Findings from the Italian study point out to potential 
misdiagnosis of women who are likely to transmit CMV 
to their offspring using serological tests. Therefore, 
determination of CMV DNA in blood (DNAemia) and 
that shed into other body fluids (viral shedding) 
presents a much more relevant and reliable test for 
active infection and potential vertical transmission in 
pregnant women.  
In addition to CMV serology, one study reported 
CMV DNAemia as well as CMV shedding in various 
specimen types in pregnant women in the Gambia [31]. 
While CMV seropositivity was 100% in the Gambian 
population, CMV DNA prevalence was much lower in 
the different sample types tested: 29% in colostrum, 
14% in vaginal swabs, 13% in saliva, 2% in plasma and 
1% in urine [31]. It would have been interesting to 
compare the CMV DNA prevalence results with CMV 
avidity results to determine the concordance of the 
results. None of the studies included in this review 
provided such information. The 29% percent CMV 
DNA detection in colostrum suggests a huge 
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contribution of breastfeeding to early vertical 
transmission of CMV [31]. 
Studies from Kenya, Sudan and one of the two from 
Nigeria report the lowest CMV seroprevalence 
frequencies (< 80%) [34,36–37], while the rest of the 
studies reviewed reported frequencies greater than 90% 
[29–33,35,38–39]. The differences in the prevalence 
rate across the African populations could be due to 
differences in other suggested or reported risk factors 
for CMV infection as well as study designs. 
 
Factors associated with acquisition of CMV in African 
pregnant women 
HIV co-infection 
Despite the reported association between CMV and 
HIV pathogenesis, there is a research gap on studies 
comparing prevalence of CMV between HIV-infected 
and HIV-uninfected pregnant women in African 
populations. For example, the 100% CMV IgG 
seroprevalence reported in the only two studies 
included in this review that considered CMV/HIV 
coinfection may not be representative of the general 
Malawian and Gambian populations, but rather 
influenced by the HIV co-infection [31,39]. 
CMV, like other herpesviruses, may lie latent after 
initial infection if viral replication is significantly 
suppressed by T-lymphocytes [46]. CMV is reactivated 
later when the immune system fails to mount an 
adequate cell-mediated immune response to contain 
CMV replication, resulting in viral shedding. 
Consequently, the immune-compromised HIV-infected 
individuals are at a greater risk of CMV reactivation 
compared to HIV-uninfected individuals [47]. As a 
result, the risk of CMV reactivation is even higher in 
HIV-infected pregnant women whose already HIV 
compromised immunity is further down-regulated in 
pregnancy [3]. Some studies have observed that 
virtually all HIV-infected women are CMV IgG 
positive. Furthermore, CMV-specific IgG avidity 
results from these studies suggest reactivation of 
subclinical infection [48–49. The dynamics of HIV and 
CMV coinfection are not fully understood but the two 
have been found to co-activate each other in vitro [50]. 
Both CMV and HIV preferentially replicate in an 
activated environment, and there was a linear 
relationship between CMV and HIV viral load in the 
Kenyan infant study [51]. The relatively high 
prevalence of CMV in Africa could in part be driven by 
the HIV burden in the region [52]. Interestingly, one of 
the studies carried out among Nigerians showed a trend 
towards increased risk of being CMV IgG positive with 
having more than one sexual partner [34], a trend 
similar to what has been observed in risk of HIV 
infection [53]. Per contra , Barbosa et al. did not find 
any relationship between number of sexual partners and 
CMV viral shedding among Brazilian women [6]. 
CMV infection is an independent predictor of 
morbidity and mortality in HIV-infected individuals 
[54,55]. In a study carried out among HIV-infected 
infants in Kenya, CMV-induced increase in T-cell 
activation and apoptosis was hypothesised to contribute 
to rapid HIV disease progression in coinfected infants, 
suggesting a possible role of CMV in driving HIV-
associated morbidity and mortality [56]. In another 
study carried out to determine the relationship between 
CMV DNAemia and maternal-infant mortality, HIV 
infected infants born to CMV DNAemic women had a 
four-fold increased risk of mortality within two years 
post-partum. The finding was independent of markers 
of HIV disease progression such as CD4+ T cell count 
and HIV viral load [57]. The discordance of CMV 
seroprevalence and HIV infection has also been shown 
in the Gambian population where a relatively high 
prevalence of cCMV (5.4%) was reported among HIV 
unexposed infants [10]. It is worth noting that the 
Gambian study enrolled only healthy infants and 
excluded premature or low birth weight infants who 
would been at a higher risk of cCMV. The finding 
emphasises the potential burden of cCMV independent 
of and in addition to the high HIV burden in Africa.  
In addition to HIV, inflammatory bowel disease 
(IBD) and colitis have been associated with a higher 
risk of CMV acquisition [58]. However, none of the 
studies reviewed here investigated or reported either 
IBD or colitis as a risk factor for CMV infection. 
 
Socio-economic status 
Since CMV infection is transmitted through contact 
with infected body fluids, hygiene and hence 
socioeconomic status are important risk factors for 
CMV acquisition. The influence of education/literacy 
on CMV acquisition could be explained by the direct 
relationship between education and income which 
determines living conditions [59–60]. A study in 
Tanzania found urban residence to be a risk factor for 
CMV seropositivity when compared to rural residence 
[38]. The finding may be explained by the greater 
population densities in urban areas compared to rural 
areas, especially given that the study was conducted at 
a public medical facility, where there would be more 
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Maternal age and parity 
The association of CMV seroprevalence and 
maternal age has been attributed to hygiene habits as 
well as contact with young children who may be at a 
higher risk of shedding CMV. A study by Pass et al. 
reported higher rates of CMV infection among parents 
of children who attended day care [61]. The children in 
day care are exposed to CMV through interaction with 
their peers, hence increase risk of CMV exposure. The 
Tanzanian study reviewed here reported a significant 
association between younger maternal age and 
increased risk of CMV seropositivity. They argued that 
the older mothers have more household experience and 
are more aware of their surroundings, hence develop 
better hygiene habits which reduce risk of CMV 
acquisition or transmission [38,62]. Findings from the 
Tanzanian study are supported by findings from an 
earlier study where younger maternal age was 
significantly associated with poor hygiene and 
increased risk of CMV infection [63–64]. 
Parity is defined as the number of term pregnancies 
a woman has had, regardless of whether they led to 
spontaneous abortion, stillbirth or livebirth. In the 
Kenyan [36] study reviewed, high parity was defined as 
having more than four children prior to the current 
pregnancy, while in the Sudanese [37] study, it was 
defined as having more than five children prior to the 
current pregnancy. Both the Kenyan and Sudanese 
studies reported a significant association between 
higher parity and risk of anti-CMV IgG seropositivity. 
Other studies have however reported conflicting 
findings, likewise, with the speculation that women 
with lower parity would be younger and less 
experienced, hence at a greater risk of CMV acquisition 
and transmission [63]. Thus, the role of parity in CMV 
acquisition remains contentious with need for further 
research, perhaps using CMV DNA and IgM 




CMV infection can be transmitted through 
transfusion of CMV-infected blood [65]. It is possible 
that some participants could have received CMV-
infected transfused blood, perhaps due to lack of CMV 
screening in the blood products intended for 
transfusion. CMV acquired through blood transfusion 
could be reactivated in settings of compromised 
immunity and pregnancy, thus increasing the risk of 
vertical transmission. Presence of anti-CMV antibodies 
in transfused blood does not necessarily reflect the 
virological status of the donor, hence is not an accurate 
proxy for the risk of transmission. Thus, more definitive 
diagnostic tests such as CMV DNA PCR are critical in 
making a reliable conclusion on the safety of blood 
intended for transfusion. Unfortunately, in Africa, 
serology remains the method of choice for CMV 
screening in blood products [26]. Given the 
discrepancies in seroprevalence, avidity and CMV 
DNA status reported and discussed in earlier sections, 
pregnant women may still be receiving CMV 
contaminated blood through transfusion. 
 
Recurrent spontaneous abortion 
Recurrent spontaneous abortion is defined as three 
or more consecutive pregnancy losses. Evidence has 
shown that potentially preventable infections may 
account for up to 66% of spontaneous abortions [15,66]. 
Infections such as Mycoplasma hominis, herpes 
simplex virus type 2 as well as CMV have been found 
to lead to inflammatory processes which result in 
spontaneous abortion [66–67]. In addition to CMV 
inducing inflammatory processes that increase 
apoptosis in trophoblast cells during pregnancy, CMV 
also activates TNF-α, leading to cell death [15]. 
Furthermore, CMV has also been shown to disturb 
normal physiology of placental cells, resulting in 
placental dysfunction and increased risk of spontaneous 
abortion or still birth [66,68]. The non-significant 
associations of CMV with spontaneous abortion 
reported in the Sudanese study could be attributed to an 
overrepresentation (80% vs 20%) of women without a 
history of recurrent spontaneous abortion in the study 
cohort, therefore minimising the effect of CMV on 
underrepresented women. 
 
Other possible factors associated with CMV infection 
but not evaluated in African studies 
Genetic predisposition 
Polymorphisms in host genes encoding factors 
involved in innate immunity have been found to 
influence CMV acquisition [69]. Genes coding for TLR 
as well as NK cell surface receptors have been 
implicated. 
TLRs are protein recognition receptors which sense 
the presence of pathogen associated molecular patterns 
to mediate and trigger an immune response, particularly 
nuclear factor-kappa B (NF-κB) activation and cytokine 
secretion [70]. TLR2, 4 and 9 are the major TLRs 
involved in immune responses against dsDNA viruses 
such as CMV [71]. On the TLR2 gene, carriage of the C 
allele on the 1350T>C polymorphic site and that of the 
A allele on the 2258G>A polymorphic site were 
associated with increased susceptibility to cCMV 
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infection among Japanese children [72]. Two 
polymorphisms on the TLR4 gene (896A >G and 1196 
C>T) were significantly associated with the risk factors 
for invasive aspergillosis that included CMV 
seropositivity [73]. A study performed among Polish 
foetuses and neonates reported increased risk of 
infection with 1486 T>C and 2848G>A SNPs on the 
TLR9 gene [74]. Polymorphisms that are associated 
with increased susceptibility to CMV infection involve 
a nucleotide change which results in a less potent 
protein being produced [72]. In contrast, Jablonska et 
al. reported no association between polymorphism in 
the TLR2 (1350T>C, 2258G>A) and TLR4 (896A>G 
and 1196C>T) genes and risk of cCMV infection 
among infants, but reported a decreased CMV infection 
risk in adults carrying the TLR2 2258A allele [75]. 
Polymorphisms in the TLR genes that confer protection 
against CMV infection encode potent and relatively 
highly functional TLR proteins. 
NK cells expressing the human leukocyte antigen 
(HLA) E-binding receptor NKG2C have been found to 
be particularly important for CMV control [76–77]. A 
deletion in NKG2C, a gene that encodes for the NKG2C 
receptor protein has been associated with decreased 
absolute number of NKG2C+ NK cells, with a 
decreased expression of NKG2C receptors on the NK 
cell surface as well as lower activation and 
degranulation of NKG2C+ NK cells. Studies have found 
transplant patients who are heterozygous or 
homozygous for the deletion to be at an increased risk 
of CMV reactivation and symptomatic CMV disease 
after immunosuppressive therapy [78]. It is important to 
note that the allele and genotype frequencies of the 
NKG2C deletion differ across populations [79] and so 
findings may not be generalised. Genetic findings 
should therefore be population-specific especially 
considering the genetic differences between Africans 
and other world populations, and the extensive genetic 
diversity within Africa. Of note is the high prevalence 
of the NKG2C deletion among African population 
compared with other populations. The NKG2C 
genotype frequencies further demonstrate a striking 
difference between East and West Africans [79]. 
Variation in genes encoding human leukocyte 
antigen (HLA) and killer cell immunoglobulin like 
(KIR) receptors have also been widely implicated in 
susceptibility or resistance to infection and disease 
progression of various viruses due to their critical role 
in immune regulation [80]. Considering that CMV has 
an extensive repertoire of mechanisms for immune 
evasion, polymorphisms in genes encoding proteins 
involved in the immune cascade such as IL, IFN and 
TNFα may play a role CMV infection [81]. However, 
relatively little is known about genetic predisposition to 
CMV infection and transmission, particularly in the 
African setting, yet knowledge of such genetic 
determinants may yield novel therapeutic targets for 
CMV. 
 
Gut microbiome profiles 
Gut microbiome profiles shape the microbial and 
immunological environment of the gut, hence indirectly 
protect against pathogenic infections and influence 
immune responses [82–83]. An altered microbiome has 
been associated with an increased risk of disease 
acquisition, with some bacterial species being 
protective against infection while others have a more 
pro-inflammatory effect. Gut microbiome dysbiosis in 
pregnancy may weaken immunity, thereby facilitating 
antenatal infections such as CMV which place the 
developing foetus at risk [84–85]. In addition to the 
possible pregnancy induced microbiome dysbiosis, 
CMV replication in the gut epithelia has been 
associated with disruption of the tight junctions of the 
gut epithelia which results in increased intestinal 
permeability [86]. This effect of CMV on the intestinal 
epithelia has been found to be partly mediated by the 
CMV-induced proinflammatory cytokine IL-6. The 
effect of CMV on the integrity of the gut epithelia has 
been described in HIV-coinfected individuals [87], 
leading to disruption of the gut barrier and microbial 
translocation, which in turn fuel immune activation and 
inflammation and result in poorer outcomes [83]. CMV, 
independent of HIV, results in the tight junction 
disruption as treatment with letermovir, an anti-CMV 
drug, dampens the effects of CMV on the gut by 
restoring the epithelia [87]. As such, CMV infection 
may be associated with certain aberrations in gut 
microbiome profiles [88]. A recent longitudinal study 
found that gut colonisation by Staphylococcus aureus 
was protective against early acquisition of CMV 
infection [89]. Barton et al. reported that latent CMV 
infection confers protection against symbiotic bacterial 
infection [90], further emphasizing the possible role of 
CMV on the normal gut flora. However, none of the 
studies reviewed here investigated possible 
relationships between CMV infection and gut 
microbiome profiles, so this represents an important 
area for future research. 
 
Immune activation 
Immune activation is characterised by chronic 
inflammation and stimulation of immune cells, which 
in turn secrete inflammatory factors such as cytokines 
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and chemokines in response to infection or immune 
dysregulation [91]. In addition, there is sustained 
immune cell proliferation which exhausts naïve 
immune cells. This immune environment facilitates 
inflammation and viral replication in host cells, hence 
increasing chances of viral shedding into the mucosa 
and body fluids. CMV has been described as a disease 
of inflammation in pregnancy [92], but the dynamics of 
immune activation, CMV DNAemia and CMV 
acquisition/transmission are unknown. In the study 
carried out among Kenyan HIV-infected infants, 
mentioned earlier in this review, the CMV-induced 
increase in T-cell activation and apoptosis observed 
could potentially be a marker of CMV-induced immune 
activation [51]. Also, since CMV has been found to 
have a synergistic intracellular co-activation with HIV, 
it is possible that CMV is also sustained by chronic 
immune activation [47]. The ability of CMV to evade 
host innate immunity may also implicate CMV 
infection in chronic immune activation. Interestingly, 
chronic immune activation is associated with gut 
microbiome dysbiosis [85]. However, not much work 
has been done into investigating the role of chronic 
immune activation in sustaining CMV infection. 
 
Conclusion 
The risks of CMV infection and reactivation are 
determined by a variety of host, viral and environmental 
factors. However there still is a knowledge gap on the 
extent to which these various factors are operating in 
Africa, especially compared with the developed world, 
yet Africa is one of the regions with the greatest CMV 
burden. In the absence of a vaccine, it would be 
worthwhile to develop more rigorous and sensitive 
diagnostic tools, especially targeting women in the 
reproductive-age group, who have the greatest potential 
risks for CMV acquisition and reactivation with the 
consequent risk of vertical transmission. The initiation 
of CMV education to women by the American Medical 
Society resulted in a drastic decrease in CMV 
prevalence [93]. It might therefore also be valuable to 
educate African women on the possible effects of 
maternal and congenital CMV infection and the 
necessary steps to avoid acquisition and transmission to 
the fetus and neonate, wherever and whenever possible. 
Most of the studies investigating the role of HIV in 
CMV infection were carried out prior to the roll-out of 
the universal Option B+ (lifelong ART regardless of 
CD4+ Tcell count) by the WHO. The role of ART in 
CMV reactivation and risk of cCMV in HIV exposed 
children remains unclear. Studies on the potential role 
of ART in reducing risk of cCMV among HIV exposed 
infants are especially needed in Africa where there is a 
high burden of HIV. High birth rates of HIV exposed 
children who have been described to be more prone to 
disease and disability compared to their HIV-uninfected 
counterparts also necessitates these studies. This is 
further emphasized by several studies which have 
reported cCMV rates of between three and 11% in HIV 
exposed infants, potentially contributing to hearing loss 
and other disabilities in HIV-exposed children. As 
reviewed by Manickal et al. [1], in South Africa alone, 
over 18,000 infants are estimated to be born with cCMV 
infection each year [1]. In addition to the HIV burden, 
a study by Slyker et al. reported a discrepancy in the 
rate of CMV DNA detection in plasma, cervical 
secretions and breast milk samples [94]. This points to 
the possibility of missing potentially transmitting 
mothers using only the widely-used plasma samples. 
Hence, there is need for more studies exploring 
methods of detecting CMV in different body 
compartments in the pregnant women and determining 
their predictive value for vertical transmission, so as to 
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Set on the given background, this thesis therefore aimed to determine the prevalence of CMV 
infection as well as factors associated with CMV reactivation in a cohort of pregnant 
Zimbabwean women. Furthermore, we aimed to determine the role of CMV infection and 
CMV susceptibility host genetics on gut bacterial profiles 
1.8 Rationale 
Although most CMV infections are asymptomatic, certain patient groups such as pregnant 
women, HIV infected individuals and infants are at risk of develop serious illnesses. CMV 
infection during pregnancy may be transmitted to the developing foetus and early neonate 
resulting in congenital CMV. The consequences of cCMV include mental and developmental 
disorders as well as sensorineural hearing loss for which CMV is the leading non-genetic 
cause. In addition to vertical transmission, CMV, infection of gut epithelial cells can result in 
a ‘leaky gut’ which is characteristic of gut bacterial dysbiosis. Gut microbiota plays a 
significant role in maternal immunity as well as the immunity and neurodevelopment of the 
foetus via the gut-brain axis. Maintenance of a healthy eubiotic gut microbiota is therefore 
essential in pregnancy   
 
Prevalence of both maternal CMV and cCMV is higher in the developing world compared to 
the developed word. In addition to unavailability of an effective vaccine, treatment of both 
maternal and congenital CMV is complicated by the largely asymptomatic nature of the 
infection. Furthermore, costs of the recommended drugs for the treatment of CMV make them 
highly inaccessible to the developing world. These factors together with the high birth rate in 
the developing world warrant an investigation into the possible factors that may predispose 
pregnant women to CMV infection. Knowledge of predisposing factors and effects of CMV 
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infection may allow identification and prioritization of women in need of intervention to curb 
antenatal CMV infection and its potential effects. 
1.9 Specific Objectives 
To accomplish the above aims, participants meeting inclusion criteria were recruited so as to 
achieve the objectives outlined below: 
1. Determination of the seroprevalence of CMV infection in HIV-infected and HIV-
uninfected pregnant women.  
2. Investigation of possible effects of efavirenz (as a proxy for antiretroviral therapy) exposure 
on acquisition of CMV during pregnancy.  
3. Determination of the role of polymorphisms in genes which encode pattern recognition 
proteins (TLRs 2,4,7 and 9) and immune cascade proteins (IL-1A, IL-6, IL-6R, IL-10, IL-
28B, IFNAR1) involved in response to CMV infection. 
4. Comparison of gut microbiome profiles of CMV infected and CMV uninfected pregnant 
women and evaluation of any association between microbiome profiles and CMV-
susceptibility host genetic variants.   
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2 Chapter 2: General Methodology 
 
Synopsis  
This chapter gives an overview of the methodology and experimental processes followed in 
meeting objectives of the overall thesis. Specific and detailed methodologies will be given in 
each manuscript and or publication.  
 
2.1 Study design and setting 
This was a cross-sectional study nested in the University of Zimbabwe College of Health 
Sciences Birth Cohort (UZ-CHS BC). The UZ-CHS BC aims to examine the impact on 
pregnancy outcomes, infant growth, immunity, and neuro-development of a range of factors, 
including co-infection with persistent viruses, maternal nutritional status and breastfeeding, 
together with maternal HIV status, levels of immune suppression and immune activation, and 
ART regimens in the HIV+ women. Participant recruitment was done at three of Harare city 
council high density suburb clinics namely Kuwadzana, Dzivarasekwa and Glenview. The 
Harare polyclinics are public health facilities which provide routine antenatal services through 
to post-natal care for mothers and their infants residing in and around the suburbs. The set-up 
of these polyclinics is the same as all the other public polyclinics throughout Zimbabwe. 
Harare is the capital city of Zimbabwe with an estimated population of 1.6 million. Harare is 
broken down into low, medium and high-density suburbs mainly according to population 
density. Each of all the suburbs in Harare has one city council clinic which provides primary 
health care, including antenatal care to residents.  Sampling for this study was done in high 
density suburbs. 
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2.2 Ethics statement 
The UZ-CHS BC and the present study both received ethical clearance from the Medical 
Research Council of Zimbabwe with file numbers MRCZ/A/2177 and MRCZ/A/1968, 
respectively. Ethical clearance was also granted by the Parirenyatwa-University of Zimbabwe 
Joint Ethics Research Committee (JREC/111/17) and the University of Cape Town Ethics 
Review Board (628/2017). Study procedures and objectives were explained to potential 
participants by trained nurses and or study staff prior to enrolment. Only participants who 
provided written informed consent for both their participation and that of their to-be-born 
infants were recruited. To protect integrity and privacy of personal and clinical information, 
participants were assigned study numbers which were used throughout the study. All human 
and health research procedures were in accordance with the ethical standards of the 
committees responsible for human research (Institutional and National), as well as with the 
Helsinki Declaration of 1975, as revised in 2008. 
2.3 Study participants and samples 
HIV-infected and HIV-uninfected pregnant women in late gestation ≥20 weeks, were 
successfully enrolled under the UZ-CHS BC. HIV-infected women were consecutively 
enrolled while for the HIV uninfected women were systematically enrolled to include every 
10th person presenting based on the approximated HIV prevalence of 10% in Zimbabwe. The 
HIV status of the participants was obtained from clinic records but additional confirmatory 
HIV testing based on the national rapid test algorithm, at the time of sample collection. The 
current standard care for HIV-infected women, regardless of CD4+ count or HIV viral load is 
ART (Option B+) to prevent HIV MTCT, which usually consists of TENOLAM-E 
(Tenofovir, Lamivudine and Efavirenz). A pretested questionnaire was administered to collect 
demographic data and medical history. Women in late gestation (>20 weeks), aged 18-50, 
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with a known HIV status or who are willing to be tested for HIV were recruited into the study. 
The HIV participants were only enrolled into the study if they had been on antiretroviral 
therapy for at least 6 weeks. Furthermore, participants were unrelated, of African (Bantu) 
origin who gave written conset for their participation and that of their to-be-born infants. 
Exclusion criteria included being non-ambulatory, mentally ill as well as history of and 
laboratory test results suggestive of underlying liver disease.  
Demographic characteristics such as HIV status, age, gestational age, parity, body mass index 
(BMI) and monthly income were collected. Recruitment of participants and collection of 
samples was carried out by trained study staff and midwives. On recruitment, the following 
samples were collected; 5ml whole blood in EDTA tube, 5ml blood in plain tube and stool. 
Plasma and serum were immediately separated and all sample stored at -80oC until analysis. 
 
The recruited pregnant women were followed up at delivery where the infants were also 
enrolled into the study and the mother-infant pairs followed up for two years post-delivery. 
Samples including amniotic fluid, breast milk, maternal and infant whole blood and infant 
stool were collected at each of the follow-up visits. The UZ-CHS BC recruited a total of 527 
pregnant, three of whom did not have sufficient data and were excluded from all study 
aspects. Of the 524 enrolled participants, 280 were HIV infected and 247 were HIV 
uninfected. Results on CMV DNA status of participants, determined by real time PCR were 
also available from the cohort database. Due to loss to follow up and other factors, the 
numbers of participants and samples available for the various objectives were not consistent. 





Figure 2.1: Participant and sample distribution for specific thesis objectives 
2.4 Laboratory measurements 
2.4.1 Determination of CMV infection status 
Detection of anti-CMV IgG and IgM antibodies as well as determination of IgG antibody titre 
and IgG avidity in serum was done using enzyme linked immunosorbent assays (ELISA) as 
described in the method section of Chapter 3.1. 
 
2.4.2 Determination of plasma efavirenz concentration 
Efavirenz in plasma was separated, identified and quantified using high performance liquid 
chromatography (HPLC). HPLC was used to separate EFV from other substances in plasma 
by passing through a column which acts as an adsorbent at high pressure, depending on how 




2.4.3 DNA extraction, amplification, genotyping and sequencing 
Extraction of host DNA was done on stored whole blood using a commercial kit as indicated 
in Chapters 3.2 and 3.3. Following mechanical lysis of bacterial cells by bead beading, 
extraction of gut bacterial DNA was extracted from stool samples using a commercial kit as 
indicated in detail in Chapter 4.4. Restriction fragment length polymorphism and Taqman 
were used to genotype for CYP2B6 c.516G>T and c.983T>C respectively as described in 
chapter 3.2. IPLEX MassArray platform, using the Agena protocol was used to genotype for 
the host genes that encodes proteins involved in immunity against CMV (characterized genes 
are listed in methods section of chapter 3.3). PCR amplification of the v4 region of 
16SrRNA gene was carried out as instructed by manufacturer of reagents, and is described in 
the methods section of chapter 3.4. Subsequent sequencing of the amplicons was done on the 
Illumina Miseq platform, also described in the same section. 
2.5 Statistical analysis and bioinformatics 
STATA 15, Graphpad Prism (v6) and R were used for descriptive and comparative statistics. 
Statistical methods employed for various objectives are described in respective chapters. 
Bioinformatics analysis as well as diversity comparison for bacteria profiles were done using 
QIIME 2 and LefSe, respectively (as described in Chapter 3.4). For all statistical tests, 








3 Chapter 3: Results 
 
Chapter three is divided into four main sections, each responding to a particular objective and 
consisting of relevant publications or manuscripts. Each main section will be indicated with a 
synopsis and summary of findings.  
 
3.1 Determination of the seroprevalence of CMV infection in HIV-infected 
and HIV-uninfected pregnant women  
 
Synopsis  
This section presents results on the objective that seek to determine seroprevalence of CMV 
infection among HIV -infected and -uninfected pregnant. This section consists of a paper 
which was published in the Viral Immunology journal (available on this link: 
https://www.liebertpub.com/doi/10.1089/vim.2019.0024).  
 
3.1.1 Seroprevalence of cytomegalovirus infection among HIV-infected and HIV-
uninfected pregnant women attending antenatal clinics in Harare, Zimbabwe 
 
Nature of publication: Original research article 
Journal/Publisher: Viral Immunology/Mary Ann Liebert Inc. 
Candidate’s contribution: conception of the project, data and sample collection, laboratory 
analysis of samples, data analysis, drafting of manuscript, incorporation of co-authors’ 
comments and execution of reviewers’ comments. 
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On investigating the seroprevalence of CMV infection and risk factors associated with 
CMV acquisition among pregnant women in Zimbabwe, the following main findings are 
summarised:   
 
• 524 women; 278 HIV-infected and 246 HIV-uninfected were recruited. 
• Current or active CMV infection defined as IgM positive + low avidity was detected in 
4.6%, 95%CI; 3–6.9 in all women, 5.8 (16/278) in the HIV-infected and 3.3% (8/246), 95%; 
1.4–6.3 in the HIV-uninfected.  
• IgG seroprevalence was 99.6% (522/524), 95%CI; 98.6–99.9 in all women.  
• No significant difference in the prevalence of active CMV infection between the HIV-
infected and HIV-uninfected women  
• The study shows a low prevalence of primary or active CMV infection among the 
pregnant women, but the IgG seroprevalence suggests high previous CMV exposure. 
• CMV seroprevalence was not associated with the HIV status of the women, perhaps due 



















3.2 Investigation of possible effects of efavirenz (as a proxy for 
antiretroviral therapy) exposure on acquisition of CMV during 
pregnancy 
Synopsis  
From the 524 recruited participants, 278 were HIV infected who were then divided into 
CMV -infected and CMV -uninfected groups, who were then assigned as cases and 
controls, respectively (see Figure 2). ART has resulted in restoration of longevity and 
normalcy of lives of people living with HIV and AIDS to approximate that of their HIV -
uninfected counterparts, if well managed. Notably, 75% of the participants who were 
positive for CMV DNA were HIV infected. It is known that regardless of the same dosage, 
not all patients achieve the same concentration of drug in their plasma yet, disease or 
infection control is dependent on optimum therapeutic drug exposure. We therefore set out 
to determine the role of antiretroviral drug exposure (using EFV as a proxy) in predisposing 
some HIV infected pregnant women to CMV infection. This chapter comprises a 
manuscript accepted for publication in the South African Medical Journal. Supplementary 
Table 1 is in the Annex section.  
 
3.2.1 Plasma efavirenz concentration inversely correlates with increased risk of 
Cytomegalovirus infection in HIV infected pregnant women 
Nature of manuscript: Original research article 
Candidate’s contribution: conception of the project, data and sample collection, 
genotyping of SNPs, data analysis, drafting of manuscript, incorporation of co-authors’ 
comments and execution of reviewers’ comments. 
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On determining the role of EFV exposure on susceptibility to CMV infection, the findings 
are summarised as follows:  
• There was an inverse association between plasma EFV concentration and CMV DNA,  
Participants with lower plasma EFV concentrations were significantly (p<0.001) more 
likely to be CMV DNA positive compared to participants with higher plasma 
concentrations.  
• Carriers of CYP2B6 poor metaboliser genotypes (CYP2B6 c.516T/T and c.983T/C) 
were less likely to be positive for CMV DNA.  
• Furthermore, poor metabolism as denoted by CYP2B6 c.516T/T and c.983T/C 
genotypes was significantly associated with lower CMV viral load. 
• Overall, the findings suggest failure of low or subtherapeutic EFV concentration to 

















3.3 Determination of the role of polymorphisms in genes which encode 
pattern recognition proteins (TLRs 2,4,7 and 9) and immune cascade 
proteins (IL-1A, IL-6, IL-6R, IL-10, IL-28B, IFNAR1) in CMV 
reactivation during pregnancy 
Synopsis  
Susceptibility to CMV infection has been mainly attributed to imbalanced immunity. 
Functions of the immune system are regulated at genetic level. It is therefore important to 
determine the role of genetic variation in genes that encode proteins involved in immunity 
against CMV, as markers of susceptibility to CMV infection. This chapter addresses 
objective 3 which sets out to determine the role of host genetic variation in susceptibility to 
CMV infection in pregnancy. This Chapter consists of a manuscript that has been submitted 
to BMC Genomics. Supplementary Table 1 is in the Annex section.   
 
3.3.1 Genetic variation in toll like Receptor 2, 7, 9 and interleukin-6 influences risk of 
Cytomegalovirus infection in pregnancy 
 
Nature of manuscript: Original research article 
 
Submitted to: BMC Medical Genetics 
 
Candidate’s contribution: conception of the project, data and sample collection, 
laboratory analysis of samples, initial data analysis, drafting of manuscript, incorporation of 
co-authors’ comments and execution of reviewers’ comments. 
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The findings from this study can be summarised as follows: 
 
• This study is the first to report on genotype and allele frequencies of SNPs in TLR2, 
TLR4, TLR9, TLR7, IL-6, IL-10, IL-28B, IL-1A and interferon AR1 (IFNAR1) genes in a 
Zimbabwean population. 
  
• The TLR2 rs1816702C/C (p=0.002), TLR7 rs179008C/C (p<0.001) and TLR9 
rs352139C/C (p=0.003) genotypes were associated with a CMV+ status.  
 
• In contrast, the interleukin (IL)-6 rs10499563T/C genotype was associated (p<0.001) 
with CMV- status.  
 
• Despite previous reports on association of the SNPs in TLR4, IL-10, IL-28B, IL-1A and 
IFNAR1 genes with CMV and other viral infections, in our study we did not observe and 
significant association between antenatal CMV and these SNPs.  
 
• The lack of significant association between CMV infection status and the other SNPs 
could be due to: (i) low frequency in the study population, (ii) linkage disequilibrium with 
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Background: Maternal cytomegalovirus (CMV) infection and/or reactivation in pregnancy is 
associated with a myriad of adverse infant outcomes. However, the role of host genetic 
polymorphisms in modulating maternal CMV status is inconclusive. This study investigated the 
possible association of single nucleotide polymorphisms in toll like receptor (TLR) and cytokine 
genes with maternal plasma CMV DNA status in black Zimbabweans. 
Results: The TLR2 rs1816702C/C (p=0.002), TLR7 rs179008C/C (p<0.001) and TLR9 rs352139C/C 
(p=0.003) genotypes were associated with a CMV+ status. In contrast, the interleukin (IL)-6 
rs10499563T/C TLR2 rs1816702C/C (p=0.002) genotype was associated (p<0.001) with CMV- 
status. Furthermore, genotype and allele frequencies of SNPs in TLR2, TLR4, TLR9, TLR7, IL-6, IL-
10, IL-28B, IL-1A and interferon AR1 (IFNAR1) genes are being reported here in a Zimbabwean 
population.  
Conclusions: Toll like receptor and interleukin genetic polymorphisms influence CMV status in late 
gestation among black Zimbabweans. This is attributable to possible modulation of immune 
responses to CMV reactivation in a population that was previously exposed to CMV infection.  
Background 
Seroprevalence of Cytomegalovirus (CMV) amongst women of reproductive age ranges from 40-
65% in the developed world and can reach 100% in developing countries  [1, 2]. CMV infection in 
pregnancy, in the setting of both primary infection and reinfection, can be potentially transmitted to 
the foetus and or neonate, resulting in congenital CMV (cCMV).  The consequences of CMV range 
from asymptomatic viraemia to potentially life changing conditions which include mental 
retardation and congenital sensorineural hearing loss. Studies have implicated maternal 
demographics, socioeconomics and HIV status among the strongest determinants of the biased 
occurrence and vertical transmission of CMV [3–7]. Furthermore, maternal immune responses to 
CMV infection and/or reactivation actively modulate CMV related disease outcomes [8].  Thus, 
variation in genes that encode components of the immune system that are directly or indirectly 
involved in the pathogenesis of CMV have been implicated in CMV infection outcomes [9]. 
However, the genetic variants, like seroprevalences and the factors influencing CMV epidemiology 
are heterogenous among populations hence research findings are equivocal.   
Toll-like receptors (TLR) are crucial in  the detection of viruses in circulation and the subsequent 
elicitation of an antiviral response [10, 11]. TLRs act as pattern recognition receptors of non-
methylated viral CpG-containing DNA which signals the presence of CMV infection [12]. TLR2 
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and TLR4 are cell surface receptors while TLR3, -7 and -9 are endosomal receptors [13, 14]. TLRs  
facilitate viral attachment and entry resulting in CMV-elicited signalling antiviral responses such as 
type 1 interferon activation of nuclear factor kappa β (NF-k β) and pro-inflammatory cytokine gene 
expression [12, 15]. Activation of the type 1 interferon producing cascade and production of 
cytokines form the major cellular antiviral mechanisms against CMV [16–18]. Single nucleotide 
polymorphisms (SNPs) in the TLR2, TLR4, TLR7 and TLR9 genes were inconclusively reported to 
be associated with CMV infection [19–23]. 
In response to TLR activation, chemokine (interleukin and interferon) genes signal immediate 
secretion of ILs from cells such as macrophages and T-helper cells.  Chemokines that trigger an 
immune cascade by signalling direct growth, development, maturation, activation and increased life-
span of immune cells. In the case of CMV infection, chemokines signal: maturation of B-
lymphocytes into plasma cells which produce anti-CMV antibodies, and activation of cytotoxic T 
cells for destruction of CMV infected cells [24, 25].  The differential response to CMV exposure 
with some but not all exposed individuals developing CMV-related diseases suggests a possible role 
of host genetic variation in immune response. A study by Sezgin et al [26] showed that human 
interleukin-10 receptor variants potentially interfere with IL-10 binding and signal transduction 
influence susceptibility to CMV retinitis.  In a large Swiss HIV Cohort Study, the effect 
of IFNL3 TT/-G substitution, the variant allele was associated with occurrence of CMV retinitis 
[27]. The same allele was also associated with susceptibility to CMV replication in transplant 
patients [28]. 
 Detection of host genetic variants which may confer resistance to CMV infection and reactivation 
could reveal potential therapeutic targets against pregnancy related CMV disease. Furthermore, host 
genetic determinants of CMV disease outcomes could be used as predictors of adverse outcomes of 
maternal CMV. While the host genetics of CMV have been studied in other populations, a glaring 
gap in knowledge exists among Africans. The differences in genomic variation between Africans 
and other populations cannot be over-emphasised, hence findings from other populations may not be 
an accurate reflection in Africans. The aim of the present study was to determine if single nucleotide 
polymorphisms in genes that encode components of the immune system influence acquisition or 
reactivation of CMV in pregnancy.  
Results 
Study participants’ demographic and clinical characteristics 
The demographic and clinical characteristics of the 110 participants are summarised in Table 2. All 
participants were in child bearing age (median 28 years, 25th–75th percentile: 23–34). The group of 
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women with a positive CMV DNA (CMV+) status (median 24 kg/m2, 25th–75th percentile: 22–27) 
had a significantly (p=0.006) lower body max index (BMI) than the group who tested negative for 
CMV DNA (CMV-) (median 26 kg/m2, 25th–75th percentile: 24–29. CMV+ participants also had 
significantly lower systolic blood pressure when compared with the CMV- participants. Age, 
gestational age, parity, gravidity, diastolic blood pressure, pulse rate, income, level of education and 
HIV status were comparable between CMV+ cases and CMV- controls.  








Median age in years 
(25th-75th percentiles) 
28 (23–34) 29 (23–34) 28 (23–33) 0.85 
Mean gestational age, 
weeks ± sd 
32.3 ± 4.4 32.4 ± 4.8 32.1 ± 3.5 0.73 
Mean SBP, mmHg ± 
sd 
112 ± 13 113 ± 14 109 ± 9 0.037 
Mean DBP, mmHg ± 
sd 
69 ± 10 70 ± 10 67 ± 9 0.13 
Mean pulse rate, bpm 
± sd 












1 (0–2) 1 (0–2) 1 (0–2) 0.31 
Median gravidity 
(25th-75th percentiles) 
2 (1–3) 3 (2–4) 2 (1–3) 0.62 
HIV infected n (%) 73 (66) 45 (61) 28 (78) 0.08 
Median income in 
USD/month (25th-75th 










Education n (%)    0.30 
    Secondary 97 (88) 67 (91) 30 (83)  
    Primary 9 (8) 4 (5) 5 (14)  
    Tertiary 4 (4) 3 (4) 1 (3)  
Key: CMV=Cytomegalovirus, CMV+=CMV infected, CMV-=CMV uninfected, BMI=Body mass 
index 
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Association between SNPs and CMV infection 
Genotype data for the 20 SNPs genotyped was available for all 110 participants and the SNP 
rs113181057 on the IFNAR1 gene was monomorphic in the study population. There was a departure 
from Hardy-Weinberg equilibrium (HWE) for four of the 20 SNPs: TLR7 rs179008 in cases, TLR2 
rs1816702 and IL-6 rs10499563 in the controls and IFNAR1 rs2843710 in both groups. 
Supplementary Table 1 is a summary of genotype frequencies in the CMV+ and CMV- negative 
groups and the univariable logistic regression analyses of SNPs and CMV status. Using the 
univariate logistic regression analysis of codominant and log additive inheritance models, 4 SNPs 
(rs10499563 (p<0.001), rs179008 (p<0.001), rs1816702 (p=0.002) and rs352139 (p=0.003) were 
significantly associated with CMV DNA status (Supplementary Table1).  The IL-6 rs10499563T>C 
polymorphism was significantly associated with lower risk of CMV infection. When compared to 
the IL-6 rs10499563T/T genotype, the rs10499563T/C was associated with a lower risk of CMV 
infection as the genotype was significantly (p<0.001) less frequent in the CMV+ group (14%) than 
the CMV- group (70%). Likewise, the TLR2 rs1816702C>T SNP was significantly associated with 
lower risk of CMV infection. Genotype rs1816702C/C genotype was significantly (p=0.002) higher 
in the CMV+ (47%) than the CMV- women (11%). 
In contrast, TLR7 (rs179008A>T) and TLR9 (rs352139T>C) polymorphisms were associated with 
an increased risk of CMV infection. The TLR7 rs179008C/C genotype was significantly higher in 
the CMV+ group than the CMV- group (31% vs. 3%; p<0.001. With reference to the TLR9 
rs352139T/T genotype, both the rs352139T/C and rs352139C/C genotypes were significantly 
(p=0.005) higher in the CMV+ women (28% and 58% respectively) than in the CMV- women (11% 
and 47% respectively). These associations remained significant after correction for multiple 
comparisons (Figure 1). When other models of genetic inheritance were considered, the association 
of IL-6 rs10499563 maintained significant association with CMV status after Bonferonni correction 
(BC) in dominant, and overdominant models.  SNPs rs1816702 and rs179008 also maintained 
significance with CMV status after BC in the dominant and recessive models (Figure 1).  
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Fig. 1 Plot of log10 p-values for the association of gene with CMV DNA across models of genetic 
associations. For each figure panel, the lower dotted horizontal line is for the nominal p-value 
threshold for significance (0.05), while the upper dotted blue line for the Bonferroni corrected 
threshold p-value for significance. 
Table 3 shows multivariable logistic regression analysis of SNPs (rs10499563, rs179008, rs1816702 
and rs352139) that were associated with CMV status in the univariable analyses. BMI was also 
included in the model. All SNPs maintained significant association with CMV infection status in at 
least one of the models. However significant association of rs352139 with CMV status was 
borderline (p=0.049) in the log additive model while it was not significant in the other models.  
BMI’s association with CMV status also substantially attenuated in the multivariate logistic 
regression model (p=0.068). 
The IL-6 rs10499563T>C SNP was associated with low likelihood of CMV positivity in codominant 
(OR=0.05; 95%CI=0.01–0.25, p=0.001) as well as in the log additive, dominant and overdominant 
models. The result shows the association of the C allele with lower odds of CMV infection even in 
heterozygous state (rs10499563 T/C). For the TLR7 rs179008A>T SNP, the T allele was 
significantly associated with higher odds of CMV infection in the codominant model (OR=3.67; 
95%CI=0.79–116.99; p<0.011) which, was maintained in the log additive, recessive and dominant 
models. Hence T allele will likely be associated with CMV+ status in both homozygous and 
 61 
heterozygous states (rs179008T/T and rs179008A/T). The TLR2 rs1816702T>C was significantly 
associated with decreased risk of CMV positivity both in the codominant (OR=0.05; 95%CI=0.01–
0.25, p=0.001) as well as in the log additive, dominant and overdominant models. Hence, risk of 
CMV infection will be decreased in the homozygous state, rs1816702C/C. The TLR9 rs352139 was 
significantly associated with likelihood of CMV infection, only in the log additive model (OR=2.85: 
95%CI=0.95-8.58; p=0.049). 
Table 3 Multivariable adjusted models containing BMI and significant SNPs in univariable analysis 
SNP Model Genotype OR (95%CI) p-value 
TLR2 
rs1816702 
Codominant C/T 0.09 (0.02-0.43) 0.001 
T/T 0.06 (0.01-0.48  
Dominant C/T-T/T 0.08 (0.02-0.37) 0.0003 
Recessive T/T 0.32 90.07-1.50 0.133 
Overdominant C/T 0.29 (0.08-1.01) 0.044 
Log additive 0,1,2 0.22 (0.08-0.62) 0.001 
TLR7 
rs179008 
Codominant A/T 3.67 (0.79-116.99) 0.011 
T/T 18.69 (1.59-220.04)  
Dominant A/T-T/T 6.05 (1.53-23.94) 0.006 
Recessive T/T 13.15 (1.15-149.74) 0.013 
Overdominant A/T 2.27 (0.53-9.68) 0.262 
Log additive 0,1,2 4.08 (1.46-11.39) 0.003 
TLR9 
rs352139 
Codominant T/C 2.87 (0.50-16.58) 0.144 
C/C 8.13 (0.90-73.63)  
Dominant T/C-C/C 3.58 (0.65-19.66) 0.121 
Recessive C/C 3.65 (0.67-19.77) 0.124 
Overdominant T/C 1.05 (0.30-3.68) 0.938 
Log additive 0,1,2 2.85 (0.95-8.58) 0.049 
Il-6 
rs10499563 
Codominant T/C 0.05 (0.01-0.25) <0.001 
C/C 0.42 (0.05-3.77)  
Dominant T/C-C/C 0.08 (0.02-0.31) <0.001 
Recessive C/C 1.53 (0.21-11.39) 0.682 
Overdominant T/C 0.06 (0.01-0.27) <0.001 




Comparison of variant allele frequencies from this study with other populations  
The variant allele frequencies of the genotyped SNPs were compared with data from two other 
populations: Asians and Europeans. Table 4 gives variant allele frequencies for the genotyped SNPs 
in this study as well as for Asians and Europeans as reported on dbSNP.  
Table 4 Comparison of variant allele frequencies of genotyped SNPs with other populations  







TLR2 rs4696480 A 0.31 0.37 0.52 0.57 
TLR2 rs3804099 T 0.45 0.36 0.56 0.72 
TLR2 rs1816702 T 0.47 0.43 0.12 0.00 
TLR4 rs1554973 T 0.20 0.21 0.77 0.86 
TLR4 rs2737190  A 0.14 0.16 0.33 0.37 
TLR4 rs10759932 C 0.19 0.25 0.85 0.76 
TLR4 rs7856729 T 0.38 0.33 0.13 0.10 
TLR7 rs179008 T 0.23 0.12 0.23 0.00 
TLR9 rs352139 C 0.42 0.61 055 0.40 
TLR9 rs5743836 G 0.36 0.42 0.13 0.00 
TLR9 rs187084 G 0.30 0.29 0.43 0.40 
TLR9 rs352140 T 0.32 0.29 0.55 0.39 
IL-6 rs10499563 C 0.31 0.27 0.23 0.16 
IL-6R rs4537545 C 0.26 0.34 0.37 0.32 
IL-10 rs1800872 T 0.40 0.44 0.24 0.68 
IL-10 rs1878672 C 0.25 0.26 0.45 0.05 
IL-28B rs12979860 G 0.70 0.82 0.86 0.97 
IFNAR1 rs2843710 G 0.30 0.31 0.41 0.36 
IFNAR1 rs113181057 C 0.00 N/A N/A N/A 
IL-1A rs1800587 C 0.65 0.60 0.71 0.93 





The outcome of an infection is determined, in part, by the intensity of the inflammatory response 
[32], which varies between individuals and can be regulated at the genetic level [33]. In this study, 
we hypothesised the possible contribution of genetic variation to the biased occurrence of CMV 
infection among pregnant women. SNPs may influence the rate and regulatory dynamics of gene 
transcription, stability of mRNA as well as production and biological activity of resultant protein. 
We therefore investigated possible association between CMV infection and SNPs in 19 genes which 
encode proteins that are or may be involved in the immune reaction cascade against CMV. The 
departure from HWE in polymorphic SNPs is due to their association with CMV infection mainly 
because the departure is being observed when cases and controls are separated but HWE is 
maintained when the two groups are combined. We report a significant association between each of; 
rs10499563, rs179008, rs1816702 and rs352139 SNPs and CMV DNA status. To our knowledge, 
this is the first report on SNPs and CMV infection in an African setting. 
To minimise the confounding effects of age and HIV status, which are directly related to immune 
function, enrolled participants were age and HIV status matched. The observation that overweight 
women were less likely to be CMV+ contradicts findings from previous studies where CMV 
infection was associated with metabolic syndrome, higher BMI and or obesity [34, 35]. Our findings 
could be due to none of the participants having any form or history of metabolic syndrome. Hence, 
we were unlikely to observe any significant associations. The observation that CMV positivity is 
significantly associated with low systolic blood pressure contrasts with previous findings which 
have shown increasing systolic blood pressure with CMV positivity [36, 37]. It is worth noting that 
the previous studies were carried out in non-pregnant adults, hence discrepancy in findings could be 
due to the well documented effects of pregnancy on fluctuations in blood pressure [38, 39] masking 
the effects of CMV infection.     
We found an association between SNP rs10499563 (-6331T>C), located within the promoter region 
of IL6 gene which regulates the rate of IL6 gene transcription [40] and CMV DNA status. 
Individuals carrying the C allele were less likely to be CMV infected, hence likelihood of being 
CMV DNA positive decreased with genotypes T/T>>>T/C>>C/C. Individuals heterozygous (T/C) 
and homozygous (C/C) for the variant allele were significantly less likely to be CMV infected than 
individuals homozygous for the T allele (T/T). The IL6 gene codes for IL6, a versatile inflammatory 
cytokine whose function is related to its expression in the tissue. Smith et al previously reported 
higher level of serum IL6, in individuals with wildtype T/T genotype compared to individuals with 
C/C genotype, among coronary artery bypass patients (Smith et al., 2008).  
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Our findings could at least in part, be explained by results from the Smith et al study. Being a pro-
inflammatory cytokine, abundance of IL6 in circulation could promote CMV activation. In contrast, 
the low levels of IL6 associated with the rs10499563C allele would disfavour the occurrence of 
CMV infection. Serum IL6 levels were reported to be significantly higher among the CMV infected 
pregnant women compared to the CMV uninfected in a Chinese cohort [42].  
We also report an association between CMV DNA status and rs179008, a non‐synonymous A>T 
(Gln11Leu) polymorphism within exon 3 of the TLR7 gene [43]. The resulting glycine to leucine 
change has been suggested to code for a functionally impaired TLR7 protein [44, 45]. In the present 
study, the T allele was associated with significantly lower odds of CMV positivity. Individuals 
homozygous for the variant allele T/T were significantly less likely to be CMV infected compared 
to individuals homozygous for the wildtype allele A/A.  
Upon recognising pathogen associated molecular patterns (PAMP), TLR7 activate a signalling 
cascade which activates type I IFN, dendritic cells (DCs) and B lymphocytes [46]. Activated type 1 
IFN, DCs and B cells are responsible for pathogen clearance, antigen recognition and antibody 
production. The induced immune cascade is critical in CMV clearance. In the presence of the T 
allele which results in a less potent protein, an insufficient signal is mounted by TLR7, hence 
carriers of the rs179008 T allele are at a greater risk of CMV infection. The rs179008 T allele has 
been linked with unfavourable outcomes in HIV and other viral infections. The variant was 
associated with increased susceptibility to HIV-1 and decreased IFNα production in HIV uninfected 
women [47]. The T allele has also been previously associated with a higher risk of hepatitis C 
infection and cCMV. Our findings are therefore contrasting with previous reports suggesting that the 
rs179008A>T SNP could be in linkage disequilibrium with another functional SNP or epistatic gene 
which masks the effects of rs179008A>T. 
CMV DNA status was also associated with rs1816702C>T, a SNP located in intron 2 of the TLR2 
gene. The C variant was significantly more prevalent in cases than in controls which means that 
participants with the rs1816702 C/C genotype were at a higher risk of being CMV+ than those with 
rs1816702 T/T genotype. TLR2 recognise CMV glycoproteins B (gB) and gH in a process which 
facilitates entry of CMV into immune cells [15, 48]. The rs1816702 T allele is associated with 
significantly elevated levels of inflammatory monocytes expressing CD14+/TLR2+ receptors than 
rs1816702 C allele [49]. This could explain our findings of a higher risk of CMV among 
rs1816702C/C carriers because their immune response against CMV is impaired due to lower TLR2 
expression compared to the T/T. Homozygosity for the rs1816702 C allele has also been associated 
with increased odds of Mycobacteria leprae infection and inflammatory bowel disease which were 
attributable to altered NFκB-mediated inflammatory response [50, 51]. 
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The intronic SNP rs352139T>C in the TLR9 gene was also associated with CMV DNA status. 
Homozygous rs352139C/C individuals were at a significantly higher risk of being CMV+ compared 
to homozygous T/T carriers. The effect of the C allele on risk of CMV infection was also observed 
in the dominant and recessive models where the significance of the compound heterozygous (T/C) 
and homozygous (C/C) genotypes had a greater risk than the homozygous (CC) alone, relative to the 
T/T genotype in both cases. The higher risk of CMV positivity in homozygous carriers of the C 
allele suggest that the polymorphism results in a less potent protein compared to the T allele. Since 
the polymorphism is intronic, it likely creates an alternative splicing site thus, affecting mRNA 
transcription and the final protein product. A less potent protein would have decreased ability to 
form dimers that are required to illicit an immune reaction. Individuals who are homozygous T/T 
have impaired immune responses against CMV infection, hence are more likely to experience CMV 
infection or reactivation. The HIV rapid progressor phenotype has been linked to homozygosity for 
rs352139T allele also due to reduced TRL9 potency [52].  
Conflicting findings were reported reduced risk of cCMV associated with the rs352139T/T genotype 
among infants in Poland [53]. The conflicting effect of rs352139T variant have also been reported in 
bacterial infection studies in Indonesia and Mexico, perhaps due to ethnic differences [54, 55]. We 
suggest that rs352139 could be in linkage disequilibrium (LD) with a polymorphic regulatory region 
that controls TLR9 expression or serves as a functional region SNP. LD patterns differ with level of 
genetic diversity among different ethnic groups; hence the effects of one SNP may vary from one 
population to another. To determine the possible role of genetic variability in the varying 
frequencies of CMV infection among populations, the minor allele frequencies for significant SNPs 
in our study population were compared to other populations. Whether this genetic heterogeneity 
among populations plays an active role in the differential prevalence of CMV is unclear and subject 
to further research due to the strong influence of environmental factors in CMV exposure.  
Conclusions 
We conclude that TLR2, -7, -9 and IL-6 genetic polymorphisms influence CMV status in late 
gestation among the black Zimbabweans. TLRs and ILs modulate immune responses to CMV, 
hence polymorphisms in genes encoding the receptors and cytokines could interfere with the 
immune mechanisms, hence their association with CMV status.  We recommend that future studies 
consider increasing the sample size and including proteomic and transcriptomic profiles of TLRs 
and interleukins to fully understand the dynamics of these immunogenetic variants in CMV 
infection. We also recommend a mother-infant longitudinal approach that will seek to factor in the 
effect of these immunogenetic profiles in congenital CMV and its possible sequelae. 
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Materials and Methods 
Study participants 
This study was carried out among pregnant women seeking antenatal care at three polyclinics in 
Harare’s Kuwadzana, Dzivarasekwa and Glenview high density suburbs who were recruited in the 
University of Zimbabwe College of Health Sciences Birth Cohort (MRCZ/A/1968). The general 
study design, setting and participants characteristics for the main cohort are described elsewhere 
[29]. In summary, this nested sub-study enrolled 110 women aged between 18 and 42 years who 
included 36 CMV infected cases and 74 CMV uninfected, age and HIV status matched controls. 
Whole blood and plasma specimens archived at enrolment were retrieved for host genotyping and 
CMV DNA detection respectively. CMV status of participants was determined by detection of CMV 
DNA in plasma using the real time polymerase chain reaction (PCR) kit (RealStar CMV Kit v1.0, 
Altona Diagnostics, Hamburg, Germany), following manufacturer’s instructions.  
Genotyping of candidate genes 
Using candidate gene approach, 20 SNPs in 10 genes were selected for genotyping (Table 1). 
Selection of SNPS was based on the following criteria: previously reported association or plausible 
association with CMV infection and/or other viral infection, a minor allele frequency (MAF) ≥10% 
in African populations reported in the dbSNP database (Available 
from: http://www.ncbi.nlm.nih.gov/SNP/), except for the rs113181057 SNP whose MAF in African 
populations was not previously reported. Host genomic DNA was extracted from 200µl of whole 
blood using the Quick-DNA™ MiniPrep Plus Kit (Zymo Research, Irvine, CA, USA), according to 
manufacturer's instructions. All DNA samples were diluted to a concentration of approximately 
50ng/ul in preparation of genotyping. SNPs were genotyped using Iplex GOLD SNP genotyping 















Table 1 Single nucleotide polymorphisms included in this study 
 
 
Key: SNP=Single nucleotide polymorphism, Chrom=Chromosome number, TLR=Toll-like 
receptor, IL=Interleukin, IFNAR=Interferon α, UTR=Untranslated region, ↑= increased, ↓= 




Data were compiled and managed in Research Electronic Data Capture (REDCap) [30]. Statistical 
analyses were performed using Stata SE, version 15 (StataCorp, College Station, Texas, USA) and 
the ‘Genetics’ and ‘SNPassoc’ packages of the statistical package R (version 3.4.3 [2017-11-30], 
The R Foundation for Statistical Computing, Vienna, Austria). Numerical variables are described as 
either median and 25th to 75th percentiles for skewed variables or mean and standard deviation for 
normally distributed variables, with groups comparisons via Mann-Witney U-test and Student’s t-
test respectively. Categorical variables are described as frequencies and compared across groups 
Gene SNP Chrom Genomic 
region 
Functional effect 
TLR2 rs4696480T>A 4 Intron ↓transcriptional activity 
TLR2 rs3804099C>T 4 Exon ↓protein activity 
TLR2 rs1816702C>T 4 Intron ↑protein levels 
TLR4 rs1554973C>T 9 3’UTR ↓transcriptional activity 
TLR4 rs2737190G>A  9 5’UTR ↑transcriptional activity 
TLR4 rs10759932T>C 9 Promoter ↑transcriptional activity 
TLR4 rs7856729G>T 9 3’UTR Not known 
TLR7 rs179008A>T X Exon ↓protein activity 
TLR9 rs352139T>C 3 Intron ↑transcriptional activity 
TLR9 rs5743836A>G 3 Promoter ↓transcriptional activity 
TLR9 rs187084A>G 3 Promoter ↓transcriptional activity 
TLR9 rs352140C>T 3 Exon Not known 
IL-6 rs10499563T>C 7 Promoter ↑transcriptional activity 
IL-6R rs4537545T>C 1 Intron Not known 
IL-10 rs1800872G>T 1 Promoter ↑transcriptional activity 
IL-10 rs1878672G>C 1 Intron ↑susceptibility to infection 
IL-28B rs12979860T>C 19 Intron ↓protein activity 
IFNAR1 rs2843710C>G 21 5’UTR ↓transcriptional activity 
IFNAR1 rs113181057T>C 21 Exon ↓protein activity 
IL-1A rs1800587T>C 2 5’UTR ↑transcriptional activity 
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using Chi squared test. p-value <0.05 was considered statistically significant. Genotype and allele 
frequencies were calculated using ShesisPlus [31]. SNPs were tested for departure from Hardy-
Weinberg Equilibrium (HWE) expectation using a Chi square goodness of fit test. Association 
between SNPs and CMV status was determined using univariable logistic regression analysis. 
Bonferroni correction was used to account for simultaneous comparison of multiple SNPs. 
Dominant, log-additive, codominant, recessive and overdominant inheritance models were 
interrogated for association of SNPs with CMV infection. Furthermore, multivariable logistic 
regression analysis of SNPs that were associated with CMV infection in the univariable analysis was 
carried out to adjust for their effect on each other in a model that also contained BMI as covariate.  
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3.4 Comparative diversity of gut microbiota in pregnant women: effects of 
Cytomegalovirus infection 
Synopsis to Chapter 3.4 
The wide host cell tropism of CMV includes gut epithelial cells in which case it results in 
disruptions of the gut epithelial barrier. The disruption could result in leakage of substances 
from the gut which includes bacteria and their metabolites. In addition, the effects of the 
presence of CMV in the gut on other microbial species such as bacteria is not known. 
Consequences of a dysbiotic gut microbiome during pregnancy could have adverse effects 
on both the mother and developing foetus and or neonate. This chapter answers the fourth 
and last objective of the thesis, which is to determine the possible role of CMV on the gut 
bacterial profiles. It comprises a manuscript in preparation for submission to a relevant 
journal. 
 
3.4.1 Comparative diversity of gut microbiota in pregnant women: effects of 
Cytomegalovirus infection  
 
Nature of manuscript: Original research article 
 
Candidate’s contribution: conception of the project, data and sample collection, 
laboratory analysis of samples, data analysis, drafting of manuscript, incorporation of co-




Main findings from the study are summarized as follows: 
• To our knowledge, this study is the first to describe the gut bacterial profiles of 
pregnant women with respect to CMV infection  
• Most abundant phylum for both CMV-infected and -uninfected women was Firmicutes. 
• The gut microbiota of CMV-infected women had a differentially higher abundance of 
P.copri when compared to CMV uninfected women (p<0.05, q<0.05 LDA score>2.0)  
• The gut bacterial profiles of CMV-uninfected women had a differentially higher 
abundance of L.reuteri and genus Roseburia compared to CMV -infected women (p<0.05, 
q<0.05 LDA score>2.0) 
• These findings suggest diminished overall gut health in CMV infected participants due 
to diminished short chain fatty acids producing genera such as Lactobacillus and Roseburia.  
• Furthermore, the differential abundance of P.copri in CMV infected cases confirm the 
previously described chronic inflammatory nature of CMV infection. 
• Estimation of beta diversity of genotypes (dominant model) of the rs10499563, a SNP 
in the IL-6 gene showed a trend towards statistical significance (p=0.059). This potentially 
suggests the role of genetics in shaping gut bacterial profiles.  
• We previously reported the association of the rs10499563 SNP with susceptibility to 
CMV infection. Therefore, further, bigger studies could ascertain the contribution of each of 
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Introduction: The human body is home to a diverse range of microorganisms collectively referred to 
as microbiota. Emerging data suggests that diverse microbial community is regulated by host genetic 
variation, environmental and dietary factors. Normal regulation of gut microbiota is disturbed by 
invading viruses causing dysbiosis which further influences virus infectivity. In the present article, we 
explore the possible effect of CMV infection on microbiota profiles of pregnant women. CMV infects 
gut epithelial cells, resulting in gut epithelial disjunctions, potentially causing leaky gut, gut dysbiosis 
and microbial translocation. In this study, we compared the gut bacterial profiles of CVM-infected and 
CVM-uninfected pregnant women. Comparisons of gut microbiota were also done taking into account 
host genetic variation in TLR 2, 7 and 9 and IL-6 that we have shown to affect susceptibility to CMV 
infection.  
Methods: Using a case-control study, stools were collected from 13 CMV-infected (CMV+) and 26 
CMV-uninfected (CMV-) age and HIV infection status-matched pregnant women. Microbiota were 
characterised using Illumina sequencing of the V4 hypervariable region of the bacterial16S rRNA gene 
and analysed using QIIME2. Differentially abundant bacterial taxa in women with and without CMV 
were identified using Linear Discriminant Analysis (LDA) effect size (LefSe).  
Results: We reported on significant beta diversity (p=0.001, q=0.01) between CMV-infected and 
CMV-uninfected pregnant women. The gut bacterial profiles of cases had a differentially higher 
abundance of P.copri than controls (p<0.05, LDA score>2.0), while that of controls had a differentially 
higher abundance of genera Lactobacillus and Roseburia (p<0.05, LDA score>2.0). These differences 
remained significant after correcting for multiple comparisons (q<0.05). Genetic variants in genes 
known to affect susceptibility to CMV infection did not show any significant association with gut 
bacterial profiles. However, rs10499563 a SNP in the IL-6 gene showed a trend towards significance on 
Beta diversity estimation but, did not reach statistical significance. 
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Discussion and Conclusion: Microbiota profiles of individuals signify their health status. 
Lactobacillus and Roseburia, genera are associated with improved gut epithelial integrity and reduced 
inflammation, respectively. The observed low abundance of these two genera in the CMV-infected 
group could explain the gut epithelia dysjunction and chronic inflammation associated with CMV 
infection. The chronic inflammatory nature of CMV is further explained by a differentially higher 
abundance of Prevotella in cases than in controls. In as much as CMV has been described to take 
advantage of compromised immunity, it may also play a role in immunomodulation through gut 
dysbiosis. However, the trend towards association between an immune-regulating SNP and beta 
diversity of gut bacterial profiles suggests that gut bacterial profiles may be determined or regulated at 
molecular level. 
Introduction 
The intestine is considered the largest immune organ in the human body and accounts for 80% of all 
cells that produce antibodies and consequently produces the most antibodies (40 mg/kg body 
weight/day). The composition of the human intestinal microbiota plays a critical role in determining the 
immunological, physiological and metabolic functions of the intestines (1). Alterations in gut 
microbiota profiles, particularly bacteria have been shown to play a role health and disease (2). 
Furthermore, certain disease conditions have been shown to result in gut bacterial dysbiosis. High 
throughput sequencing has made it possible to accurately describe structure and diversity of intestinal 
microbiota and its alteration in pathology.  
Cytomegalovirus (CMV) is a herpesvirus that causes antenatal infection associated with disability, 
morbidity and mortality in CMV-exposed foetuses and neonates. Cytomegalovirus has been shown to 
replicate and persist in gut epithelial cells, resulting in disruption of tight junctions of intestinal cells 
(3). The disruption reduces transepithelial monolayer integrity thereby enhancing transepithelial 
permeability. The resulting permeability is characterised by translocation of gut microbial components 
and products into the systemic blood circulation, resulting in a deleterious inflammatory condition 
known as metabolic endotoxemia (4). However, it should also be noted that there is an equally strong 
argument supporting the thesis that increased susceptibility to infection, could be a result or a response 
to an already disturbed microbiome profile (5).   
The role of HIV infection in microbial translocation is well documented. Support for an independent 
role of CMV on the gut comes from  a cohort of CMV co-infected HIV patients where CMV was 
shown to independently result in disruption of the intestinal tight junctions (3). These findings were 
concluded upon observing that letermovir, an anti-CMV drug, dampened the effects of CMV on the gut 
epithelia.  In addition, a paediatric longitudinal study reported that gut colonisation by Staphylococcus 
aureus was protective against early acquisition of CMV infection (6). These findings suggest 
interactions of CMV with gut microbiota. 
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Maternal gestational microbiota profiles have been shown to play a crucial role in shaping the infant’s 
microbiota exposure. Microbiota exposure is believed to determine health and immune and 
developmental outcomes of the infant (7,8). To our knowledge, no studies have investigated the 
possible role of antenatal CMV infection on gut microbiota profiles.  Therefore, the purpose of this 
study was to characterise gut microbiota profiles of CMV-infected and CMV-uninfected pregnant 
women. We also aimed to evaluate if CMV infection status and host genetics (IL-6 - rs10499563, TLR9 
- rs352139, TLR7 - rs179008, TLR2 - rs1816702, which we previously reported to be associated with 
CMV infection status) play a role in shaping gut bacterial profiles.  
Methods 
Ethics approval 
The present study received ethical approval from the Medical Research Council of Zimbabwe 
(MRCZ/A/2177) is a sub study of the University of Zimbabwe Birth Cohort. The study was also 
cleared by the Human Research Ethics Committee at the Faculty of Health Sciences, University of 
Cape Town (628/2017).  All participants gave written informed consent for enrolment and participation 
in the study. 
Study participants and specimen collection 
This cross-sectional study was nested in University of Zimbabwe College of Health Sciences Birth 
Cohort that recruited pregnant women who were followed up till delivery. At delivery, infants of 
consenting mothers were also enrolled into the study and mother-baby pairs were followed up for two 
years. The general study design, setting and participants characteristics for the main cohort are 
described elsewhere (9). In summary, for this sub study, 39 women were enrolled and included 13 
CMV-infected (CMV+) cases and 26 CMV-uninfected (CMV-), age and HIV status matched controls. 
Information on CMV and HIV status was available from the main cohort. Cytomegalovirus infection 
status of participants was determined using real time quantitative PCR while HIV status was available 
from patients’ clinical records and confirmed at the time of sample collection, using the national rapid 
test algorithm. Participants enrolled for this study were between 22- and 40-weeks gestational age. 
Faecal specimens were collected from participants at enrolment using sterile spatulas and screw cap 
containers. Transportation of faecal specimens to the laboratory was done on ice. Specimens were 
stored at -80 °C until processing time. 
Nucleic acid extraction and 16S rRNA gene amplicon library preparation 
The first step towards DNA extraction was beat-beating mechanical lysis of the stool (50 mg) on the 
TissueLyser LT (Qiagen, FRITSCH GmbH, Idar-Oberstein, Germany). Subsequent total bacterial 
genomic DNA isolation from the lysed sample was done using the Zymobiomics DNA extraction kit 
(Zymo Research, Irvine, CA, USA), following manufacturer’s instructions. Quantification of extracted 
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DNA was performed by spectrophotometry using Nanodrop ND 1000 (Thermo Fisher Scientific Inc., 
MA, USA). Empty manufacturer provided DNA extraction tubes and a Zymo mock community with 
eight known bacteria communities, and were included blanks and extraction controls, respectively, to 
check for possible contaminants. The Zymo standard was analysed for consistence in the whole 
pipeline from extraction to sequencing (see Figure S1). Extracted blanks spiked with a known 
concentration of Mycobacterium smegmatis were also included to control for sequencing as well as 
optimise the microbiota analyses. Zymo standard comprising of a synthetic mixture of genomic DNA 
from seven known bacteria, were used as positive controls to assess library preparation and sequencing 
artefacts.  
Two polymerase chain reactions (PCRs) using primers targeting the V4 hypervariable region of the 16S 
rRNA gene were performed as previously described by Caporaso et al (10), with minor modifications. 
Two PCRs, rather than one, reduce the risk of non-specific binding when using adapters/sequencing 
primers of more than 100 bp. In the first PCR reaction, the V4 hypervariable region of the bacterial 16S 
rRNA gene was amplified using modified-F515 (5′ - GTGCCAGCHGCYGCGGT - 3′) and R806 (5′ - 
GGACTACNNGGGTWTCTAAT - 3′) primers. The reaction consisted of 12.5 μl of 2X MyTaqTM HS 
Mix (Bioline, MA, USA), forward and reverse primer (each at a10 μM initial concentration), 0.75 μl of 
dimethyl sulfoxide (catalogue no D2650, Sigma-Aldrich®, MO, USA) and 4 μl template, made up to a 
final volume of 25.25 μl using PCR-grade water (Thermo Fisher Scientific Inc., MA, USA). Cycling 
conditions included a denaturation step at 95 °C for 3 min, an amplification step at 95 °C for 30 sec, 
50 °C for 30 sec and 72 °C for 1 sec (proceeding for 10 cycles); and a final extension step at 72 °C for 
5 min. The expected fragment from the first PCR was approximately 375bp long. The second PCR used 
4 μl of product from the first PCR as template. Composite primers F515-composite (5′ - 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTNNN
NNNNNNNGTGCCAGCHGCYGCGGT - 3′) and R806-composite (5′ - 
CAAGCAGAAGACGGCATACGAGATACGAGACTGATTGTGACTGGAGTTCAGACGTGTGCT
CTTCCGATCTNNNNNNNNNNNNGGACTACNNGGGTWTCTAAT - 3′) containing adapters, 
barcodes and 12–15 staggered nucleotides (NNNNNNNNNNNN) were used in the second PCR to 
improve cluster identity and imaging in more diverse sample. Addition of barcodes was done to enable 
multiplexing of samples. The cycling conditions for the second PCR conditions were similar to those of 
the first, but with 30 cycles. The amplicon from the second PCR was approximately 400bp long. 
Product amplicons from the two PCRs were cleaned using the Agencourt® AMPure® XP PCR 
Purification kit (Beckman Coulter, CA, USA). For both PCRs, the size of PCR products was verified 
and annotated on 1.5% ethidium bromide stained agarose gels, using 100 bp DNA ladder as the 
molecular weight marker. Amplicons were quantified using the Quanti-iTTM PicoGreen® dsDNA 
Reagent (Life Technologies, CA, USA) using the Infinite M1000 Pro® microplate reader (Tecan Group 
Ltd., Grödig, Austria) equipped with Tecan i-ControlTM 1.7 software. Pooling of amplicons was done at 
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75 ng followed by quantification and purification of the library using the Nanodrop ND 1000 and 
Agencourt AMPure XP solution, respectively. The pooled 16S rRNA library was excised following 
agarose gel electrophoresis, and purified using the QIAquick Gel Extraction kit (QIAgen, MA, USA).  
16S rRNA gene amplicon sequencing 
The KAPA qPCR quantification kit (KAPA Biosystems, MA, USA), as well as the Agilent DNA 1000 
kit (Agilent Technologies, CA, USA) were used to quantify and size the library. Using these metrics, 
the library was diluted to 4 nM using Buffer EB (Qiagen, Hilden, Germany), and denatured and 
neutralized using 0.2 N NaOH and hybridization buffer. A final library was prepared, diluted and 
spiked with 4pM of internal control (20% PhiX). Prepared library was paired-end sequenced using the 
MiSeq Reagent Kit v3, 600 cycles on the Illumina Miseq platform (Illumina, CA, USA) and run 
following manufacturer’s instructions. In addition to M.smegmatis spiked controls, consistency of the 
whole procedure was determined by including duplicates and triplicates from randomly picked samples. 
Library preparation was carried out at the Division of Medical Microbiology, University of Cape Town 
and sequencing was done at Centrefor Proteomic and Genomic Research, Cape Town. 
16S rRNA gene amplicon sequence data analyses  
Raw sequence reads were analysed using quantitative insights into microbial ecology (QIIME2 
v2019.4.0) (11). The demultiplexed raw reads were first subjected to quality-filtering, dereplication, 
denoising, chimera checking, and merging using QIIME2’s built-in divisive amplicon denoising 
algorithm (DADA2) v1.10.0 (12) commands. In summary, the forward and reverse reads were both 
trimmed at position 5. In this order, the respective reads were then truncated at positions 235 and 190. 
Reads with maximum expected error (--p-max-ee) of 2.0 were discarded. Amplicon sequence variants 
(ASVs) were then inferred and assigned taxonomy using a pre-trained RDP Naïve Bayes Classifier (13) 
against the Greengenes (version 13.8) 16S rRNA database (14). The confidence for limiting taxonomy 
was set as 0.7. Further filtering was done to remove low-abundant ASVs (singletons and doubletons) 
and non-bacterial taxa, such as mitochondria, chloroplasts, archaea, and unassigned reads. Finally, an 
ASV table was constructed. Phylogeny of the ASVs was inferred from multiple sequence alignment of 
the ASVs using MAFFT v7.310 (15). 
Dominance, Shannon, Simpson, and PD whole tree and Shannon equitability indices were computed 
for alpha diversity using an in-house R script run in the RStudio (16). Alpha diversity is the diversity 
within each sample in the two study groups, while beta diversity is comparison of diversity between 
samples. Beta diversity of the gut microbiota according to participants’ metadata was computed using 
weighted and unweighted UniFrac distances, and Bray-Curtis dissimilarity metrics and similarities and 
dissimilarities of the data visualized using principal coordinate analysis (PCoA). All beta diversity 
analyses were computed at a subsampling depth of 5,768. Differences in beta diversity measures 
between participant metadata groups were tested using permutation multivariate analysis of variance 
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(PERMANOVA), with 999 permutations. The threshold for significance for both unadjusted and 
adjusted analyses were p<0.05 and q<0.05, respectively. 
Statistical analysis 
Comparison of relative abundance of microbial taxa and genera between CMV-infected and CMV-
uninfected participants and identification of differentially abundant bacterial taxa between cases and 
controls was done using linear discriminant analysis (LDA) effect size (LefSe) v1.0 (17). Comparison 
was also done for HIV status and for the four immune-related SNPs that we have previously shown to 
be associated with susceptibility to CMV infection, using the dominant genetic model (i.e, for each 
SNP, two genotype groups were compared) using genetic data already reported (unpublished data). The 
p-value for LEfSe’s non-parametric factorial Kruskal–Wallis sum-rank test was set at 0·05 while the 
threshold for differentially abundant bacterial taxa was set at a logarithmic LDA score threshold of 2.0. 
STATA v15 (StataCorp, College Station, Texas, USA) was used to compare demographic 
characteristics between CMV-infected and CMV-uninfected participants. Mann-Whitney ranksum and 
t-test were used for non-parametric and parametric variables, respectively. Chi-squared test or Fisher’s 
exact tests were used for categorical data. For all statistical tests, a value of p<0.05 was considered 
statistically significant. 
Results 
Study participants demographic characteristics 
We characterized 16S rRNA gene sequences of faecal microbiota in 26 CMV+ cases and 13 CMV- 
controls. CMV+ and CMV- participants were HIV status and age matched, hence there was no 
significant difference in age and HIV status between the two groups. The demographic characteristics 
of the 39 study participants are summarised in Table 1. The age of participants ranged from 18 to 39 
years. Gestational age, body mass index (BMI), gravidity and income were comparable between cases 
and controls since participants in the two groups were matched. Concentration of extracted gut bacterial 


















(+ vs -) 
Mean age, years ± sd 
(range) 
28 ± 6 (18–39) 27± 6 (18–39) 28± 6 (18–38) 
  
0.60  
Mean gestational age, 
weeks ± sd (range) 
32 ± 4.2 (22–38) 33 ± 4.9 (20–40) 33±4.6 (22–40) 0.48  
Median BMI (25th–75th 
percentile) 
25 (24–29)  24 (24–26  27 (24–27) 0.07 
Mean gravidity (25th–
75th percentile) 
2.6 ± 1.1 (1–5) 2.5 ± 1 (1–4) 2.8 ± 1.3 (1–5) 0.45  
HIV infected n (%)  27 (69)  11 (85)  16 (62) 0.14  
Mean income, 
USD/month (25th–75th 
percentile)   
 269 ± 124  
(50–665) 
  






CMV+: CMV infected, CMV-: CMV uninfected, BMI: body mass index, HIV: human 
immunodeficiency virus. 
 
Gut bacterial communities of participants 
A total of 725,575 high-quality filtered reads were obtained from the 39 samples with an mean reads of 
18,605 (range: 5,768-46,444). Using 3% dissimilarity as an indicator of an ASV (amplicon sequence 
variant) 1,789 ASVs were obtained which reduced to 159 after collapsing identical ASVs and removal 
of all spurious ASVs. Taxonomic classification revealed a typical human diversity profile in both 
groups (CMV+ and CMV-) at the phylum level with a total of 18 phyla which was dominated by 
Firmicutes, Proteobacteria, Actinobacteria and Bacteroidetes, in descending order. Figure 1 is a 
heatmap of the distribution of the 27 most abundant taxa according to HIV and CMV statuses of 




Fig. 1. Heatmap of the relative abundances of bacterial taxa in 39 gut microbiotas. Rows represent the 
bacterial taxa and columns the samples.  
Richness and diversity analysis  
The alpha diversity indices, including Simpson’s, Dominance, Shannon equitability and Shannon index 
were calculated for each data set. The alpha diversity of stool samples of CMV-infected and -
uninfected participants did not differ significantly using all four indices (Figure 2).  Likewise, alpha 
diversity of participants’ gut bacterial profiles did not differ according to any of the considered SNPs. 
All samples were included in determination of beta diversity and this was based on a 99.8% Good’s 
coverage (Figure S2), this sampling depth was sufficient to estimate microbial diversity (18).  To 
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evaluate the extent of similarity between the microbiota communities, beta diversity values were 
analysed based on UniFrac and Bray-Curtis distances. Principal coordinates analysis (PCoA) of the 
resultant beta diversity estimates were then visualized using EMPeror v3.1 (19) The plots of 
community structures of each faecal sample in each of the two study groups are shown in Figure 3. The 
PCoA results revealed that the overall microbial composition of CMV infected participants 
significantly deviated (p=0.001) from that of CMV uninfected participants. Hence, there was distinct 
clustering of samples from cases or controls. There was no significant difference on beta diversity 
estimation when considering all four SNPs: (rs10499563 - p=0.059, rs352139 - p=0.432, rs179008 - p= 
0.097, rs1816702 - p=0.858). There was a trend towards significant beta diversity of gut bacterial 
profiles and the rs10499563 SNP on the IL-6 gene. The PCoA for beta diversity estimation of gut 
bacterial profiles and rs10499563 is shown in Figure 4. 
 
 
Fig. 2. Alpha diversity measures of gut microbiota grouped by CMV infection status. In each plot, the 




Fig. 3. Beta diversity measures of gut microbiota grouped by CMV infection status, based on weighted 




Fig. 3. Beta diversity measures of gut microbiota grouped by rs10499563 genotype (dominant model), 
based on weighted Unifrac distance. 
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Comparison of taxonomic composition according to CMV infection status 
We searched for differentially abundant features (bacterial biomarkers) between CMV+ and CMV- 
participants using LefSe. LEfSe identified, eleven bacterial taxa were differentially abundant between 
CMV+ and CMV- participants (LDA score >2.0, p <0.05), Figure 5. There were no significant 
differences in relative abundances between the CMV+ and CMV- groups at phylum, order and class 
taxonomic levels. At family level, Lactobacillaceae was significantly less abundant in cases than 
controls (p<0.001, q=0.148, LDA score=6.6). Prevotellaceae and Exiguobacteraceae (p<0.001, q<0.05, 
LDA score=6.4 and p<0.001, q=0.174, LDA score=5.8, respectively) were significantly more abundant 
in CMV+ compared to CMV- participants. Genera Prevotella, Exiguobacterium and Lactococcus were 
identified as biomarkers for CMV infection.  Lactobacillus and Roseburia were differentially less 
abundant in CMV+ participants. 
The cladogram shown in Figure 4(a) represents the connection between the significantly different taxa 
at different taxonomic levels up to genus level. The significantly different taxa are shown in a tree like 
structure. Moreover, LDA score demonstrated that these differentially abundant taxa can be considered 
as potential biomarkers (LDA score > 4.0, ρ < 0.05). The histogram in Figure 4(b) show the individual 
differentially abundant taxa as well as their respective LDA scores. On correcting for multiple 
comparisons using a cut-off of q<0.05, genus Roseburia and L.reuteri remained differentially less 
abundant in cases than in controls. Using the same q-value cut off, P.copri remained differentially more 
abundant in cases than in controls. 
 
  
Fig. 5. (a) Cladogram showing differentially abundant taxonomic clades with an LDA score> 2.0 
(p<0.05) between CMV+ and CMV- participants. (b) Histogram of linear discriminative analysis 




Gut microbiome plays a key role in health and disease, metabolism and permeability of the gut mucosa 
to metabolically active molecules. In addition, gut microbiome profiles shape the immunological 
environment of the gut, hence indirectly protects against pathogenic infections and influences immune 
responses (20,21). The aim of the present study was to determine the possible effects of CMV infection 
on gut bacterial profiles by comparing gut microbiome profiles of CMV-infected with -uninfected 
pregnant women. Determination of gut microbiome profiles in pregnancy is crucial as it has been found 
to play a crucial role in determining birth outcomes (22). A secondary objective was to evaluate the 
association between host genetic variation that affects immune response genes and microbiome 
profiles.  
Pregnancy, particularly the differential hormone production and metabolism alters gut bacterial profiles 
with effects being observed in late gestation (7,8). An increase of gut bacteria associated with 
inflammatory and obese states, denoted by higher levels of Firmicutes, is usually observed in late 
gestation (23). As all participants studied here were in late gestation, differences observed with respect 
to bacteria profiles are highly likely not due to gestational age. Furthermore, our two groups were 
matched for demographic characteristics such as HIV status, age, gestational age, and income. 
Therefore, these factors previously identified as shaping gut bacterial profiles are not confounders in 
the present study.  
The two major phyla in our study participants (Firmicutes and Proteobacteria) were representative of 
what has been previously reported in healthy populations. Proteobacteria have been reported to be more 
abundant in developing world populations, such as the cohort in the present study, when compared with  
populations from the developed world (24). There was a trend towards higher alpha diversity in gut 
bacterial profiles of CMV+ compared with CMV- participants. Although a greater gut microbial 
diversity has been widely reported to be beneficial, it has also been associated with disease states such 
as depression and autism (25). Greater gut microbiome diversity was reported in formula-fed babies 
versus breast-fed babies (26,27). Breast-fed babies were however reported to have superior 
neurodevelopment and higher intelligence test scores when compared with their formula-fed 
counterparts (28). These studies emphasise on the segregational outcomes of higher microbial diversity, 
depending on which bacteria are present and their possible metagenomic function. On beta diversity 
estimation, cases and controls significantly differentially clustered, suggesting that CMV infection 
potentially results in different gut bacterial profiles. The trend towards significance between beta 
diversity and rs10499563 SNP suggests a role of the immune-related gene in shaping gut bacterial 
profiles.   
The presence of any possible biomarkers between cases and controls was subsequently investigated. 
From LEFSe analysis, it was observed that there were distinct bacterial taxa which were differentially 
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abundant between cases and controls. Genera Lactobacillus and Roseburia were significantly less 
abundant in CMV-infected than -uninfected participants. Lactobacillus regulates tight junction proteins 
for maintenance and protection against chemical-induced disruption of the epithelial barrier (29). It is 
for this reason the Lactobacillus forms a major component of commercial probiotics (30). In addition, 
Lactobacillus species produce short chain fatty acids (SCFAs), which play a role in maintaining host 
homeostasis and disease progression. Lactobacilli produce acetate and butyrate, which together with 
propionate, constitute ≥95% of all SCFAs (31). SCFA also participate in gluconeogenesis and lipid 
biosynthesis, thereby modulating various biological responses of host that include inflammation and 
oxidative stress.   
Low relative abundance of Lactobacillus has also been associated with inflammatory conditions such as 
ulcerative colitis and Crohn’s disease (known as inflammatory bowel disease, IBD). IBD is a classic 
example of gut microbiome dysbiosis condition (32). Roseburia, a genus which was also significantly 
less abundant in the CMV+ compared to CMV- in the present study produces butyrate, maintains 
immune function of the gut and regulates inflammation (33,34). A recent case control study reported a 
lower abundance of Roseburia in ulcerative colitis cases when compared with non- ulcerative colitis 
controls (35). Furthermore,  higher abundance of Roseburia in the gut was associated with increased 
and T-cell differentiation and reduced inflammation by inhibiting excretion of interleukin-17 (36).  
Interestingly, CMV is known as a chronic inflammation condition. We hypothesise that CMV infection 
may be characterised by the low abundance of Lactobacillus and Roseburia, further weakening the gut 
epithelia tight junctions and promoting inflammation, respectively. It is also important to note that 
CMV has been implicated in recurrent spontaneous abortion. In addition to bacterial and toxin leakage 
induced inflammation, the uncontrolled inflammation at the gut interface may lead to endometrial 
inflammation, resulting in spontaneous abortion. The haematogenous spread of microbes from a leaky 
gut to the placenta or uterus suggested by Nuriel-Ohayon et al (37), could result in endometrial 
inflammation, hence CMV-associated adverse effects on the pregnancy and developing foetus. CMV-
induced gut leakage and dysbiosis during pregnancy could potentially have detrimental effects on the 
developing foetus mainly via the gut-brain axis (22). 
Previous studies have also suggested and indicated the contribution of low abundance of SFCA-
producing gut bacterial profiles with low vaccine success (38–40). The population-wide low success 
rate can be attributed to insufficient bacterial products to induce an adequate antibody response to the 
vaccine. Control of CMV has been greatly hampered by the low success rate of the developed vaccine. 
Addition of probiotics containing organisms such as Lactobacillus and Roseburia could ameliorate 
outcomes of CMV vaccination trials.  
The differentially higher relative abundance of P. copri in cases than controls is in keep with previous 
studies that associated Prevotella abundance with boosted cytokine production and chronic 
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inflammatory conditions (41). A study carried out in HIV-infected participants reported an association 
between higher abundance of P. copri with faster disease progression and higher markers of 
inflammation (42). CMV is one such condition. However, Prevotella can be either beneficial or 
detrimental, depending on circumstances as abundance of Prevotella has also been associated with 
intake of a healthier, plant-based diet (43). Our findings suggest that CMV infection could potentially 
result in gut bacterial dybiosis.  
Our findings also suggest a role of genetics in shaping gut bacterial profiles. IL-6 gene codes for the 
pro-inflammatory cytokine which is associated with increased gut epithelial disjunction (44). Presence 
of the SNP results in reduced production of IL-6, hence the potential clustering of participants gut 
bacterial profiles of participants carrying different genotypes (45).  We recommend that bigger 
prospective and functional studies be carried out to elaborate on these relationships and to ascertain the 
role of each factor in shaping gut bacterial profiles. 
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Fig. S1. Bar chart illustrating expected bacterial percentage in the Zymo commercial standard 
alongside the yield from this study’s workflow  
  
 
Fig. S2. Rarefaction curves depicting Goods’ coverage gut bacterial sequences for all study 
participants  
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4 Chapter 4: Summary Discussion and Conclusion 
 
4.1 Summary discussion 
Antenatal CMV infection has resulted in a global burden of cCMV. The prevalence of 
CMV infection is higher and almost ubiquitous in the developing world (60-100%) than the 
developed world (0-60%), respectively (Adland, Klenerman, Goulder, & Matthews, 2015; 
Antona et al., 2017; Lantos, Permar, Hoffman, & Swamy, 2015). It has been suggested that 
the likelihood of vertical transmission of CMV is greater in the setting of primary infection 
than reinfection or reactivation (Mussi-Pinhata et al., 2018; Wang, Zhang, Bialek, & 
Cannon, 2011).  However, due to cumulative effect, the prevalence of cCMV is ten times 
greater in the developing (3%) world when compared to the developed world (0.3%), 
respectively (Kenneson & Cannon, 2007; Manicklal, Emery, Lazzarotto, Boppana, & 
Gupta, 2013; Mussi-Pinhata et al., 2009).  
Factors such as host genetic variation, socio-economic status and immune response profiles 
have been suggested and shown to influence susceptibility to maternal CMV infection. The 
factors that predispose to either antenatal CMV primary infection or infection seem to differ 
inter-individually and at population level (Lanzieri, Dollard, Bialek, & Grosse, 2014; 
Lawrence et al., 2017). Despite a higher burden of both maternal and congenital CMV 
infection in the developing world, particularly Africa, there is a knowledge gap on factors 
that contribute to the differential outcomes of CMV exposure ie. whether exposure results 
in CMV infection or not. This thesis aimed to determine the prevalence of CMV in a cohort 
of pregnant women and to investigate the role or contribution of ART exposure and host 
genetics to susceptibility of CMV infection. 
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The present study is the first to report on the prevalence of CMV infection among pregnant 
women in Zimbabwe and the high seroprevalence of anti-CMV IgG antibodies is further 
confirmation of the ubiquitous nature of CMV exposure in a low-income setting. However, 
despite the high CMV exposure, not all participants had active CMV infection during 
pregnancy or at the time of sample collection. Although immune status has been suggested 
to play a role in susceptibility to CMV infection (Hanley & Bollard, 2014), HIV infection 
status was not associated with CMV serostatus in this study. Presence of CMV DNA in 
plasma was also determined as a marker of active CMV infection. There was a discrepancy 
in the results of CMV infection status of participants using the two methods. Considering 
CMV DNA, participants who were HIV infected were more likely to be CMV infected 
compared to HIV uninfected participants. These findings confirm the inferiority of 
detection of anti-CMV antibodies as a diagnostic method for active CMV infection, as 
previously reported (S. A. Ross, Novak, Pati, & Boppana, 2011; Shannon A. Ross et al., 
2014). The underestimation of HIV infected individuals who were CMV seropositive could 
the due to these participants being so immune compromised that they are unable to mount a 
sufficient anti-IgM response to be picked by the immunoassay. However, the risk of 
detecting latent CMD DNA by PCR, resulting in false positives is also possible (Abedi et 
al., 2017). It would therefore be ideal to use both methods and rigorously rule out any 
potential CMV infected cases. PCR technology is however not readily accessible for routine 
diagnosis use especially in the developing world. As a result, the bottleneck in identifying 
antenatal CMV infection and curb potential vertical transmission of CMV will unlikely be 
resolved. 
Antiretroviral therapy has resulted in immune restoration, thereby significantly reducing the 
occurrence and episodes of opportunistic infections in people living with HIV and AIDS 
(Wilson & Sereti, 2013). The success of ART is highly dependent on maintenance of 
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optimum therapy to suppress viral replication. The optimum plasma concentrations of ART 
which are determined by rate of drug metabolism and excretion and can be approximated by 
measuring plasma concentration of the drug.  Drug metabolism and excretion outcomes are 
also largely determined at molecular level, in the genes which encode the drug metabolising 
enzymes (Prakash & Agrawal, 2016). The therapeutic range of EFV has been established, 
aiding to therapeutic drug monitoring of ART. Previous studies have shown that ART 
resulted in a decrease in the occurrence of CMV retinitis among HIV infected patients. 
Moreover, patients on CMV retinitis maintenance dose could safely discontinue anti-CMV 
therapy without any rebound (Jouan et al., 2001). Antiretroviral therapy results in immune 
reconstitution in people living with HIV and AIDS, thereby protecting them from 
opportunistic infections.  Having observed that some but not all HIV infected participants 
were CMV infected, we set out to determine the role of ART exposure in protecting 
pregnant women against CMV as an opportunistic infection. Individuals carrying the 
CYP2B6 c.516G/G and c.983T/T expectedly had low exposure of plasma EFV and were at 
a greater risk of antenatal CMV infection. Conversely, slow EFV metabolisers with respect 
to CYP2B6 genotypes (c.516T/T and c.983T/C) had higher plasma EFV exposure and 
significantly low likelihood of being CMV infected.  
All participants were on the standard 600mg/once daily EFV dose. Findings from previous 
studies have inspired policy change on universal reduction of EFV dosing from 600mg to 
400mg/once daily dose on all participants regardless of genotype. However, from our study 
findings we have shown that some women still failed to achieve therapeutic EFV 
concentration despite being on the 600mg/once daily dose. This could be due to pregnancy-
induced metabolic aberrations which also impact on drug disposition (Perucca, Ruprah, & 
Richens, 1981). As a result, caution has to be taken when prescribing ART for special 
populations such as pregnant women. Emergence of opportunistic infections such as CMV 
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during pregnancy can have detrimental effects on the developing foetus and overall birth 
outcomes. Overall, genotype-based could be an additional tool in dosing, so that we move 
away from the current practice of “one size does not fit all”. 
In addition to HIV status which is a determinant of immune functions and plays a 
significant role in susceptibility to CMV, immunity is also regulated at the molecular level. 
Variation in genes that encode proteins involved in immune pathways against CMV may 
partly explain the differential outcomes of CMV exposure regardless HIV infection status. 
Single nucleotide polymorphisms in toll-like receptors, TLR2 (rs1816702), TLR7 
(rs179008) and TLR9 (rs352139) and IL-6 (rs10499563T) genes were associated with 
differential risks of acquiring CMV infection during pregnancy. The presence of a SNP in 
the coding region of a gene may result in the coding of a protein that is structurally different 
from the normally produced protein, which could be the case with observations for TLR7 in 
this study.  When a SNP occurs in the non-coding region of a gene the effect is usually on 
the rate or quantity of protein produced, which could be the case with observations for IL6, 
TLR2 and TLR9, in this study. In either case, the ultimate function of the protein will be 
affected as either heightened or diminished. In the case of CMV associated immune 
proteins, if the SNP results in a higher protein production or a protein with greater activity, 
immunity against CMV will also be heightened. Conversely, decreased protein production 
and coding of less potent proteins will result in reduced immunity against CMV and a 
greater risk of CMV reactivation and reinfection. 
Due to the wide host cell tropism of CMV which includes gut epithelial cells, the CMV-
induced disruption of gut epithelial tight junctions is likely to result in gut dysbiosis 
(Maidji, Somsouk, Rivera, Hunt, & Stoddart, 2017). In this study we report significantly 
lower differential abundance of Lactobacillus reuteri and Roseburia in CMV infected cases 
when compared with CMV uninfected controls. Lactobacillus species have been associated 
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with maintaining integrity of the gut epithelial cells and overall health of the gut (Yu, Yuan, 
Deng, & Yang, 2015). For this reason, most of the commercial probiotics contain 
Lactobacilli species. The low differential abundance of Lactobacillus in CMV infected 
participants suggests deranged gut health in CMV infection. Low abundance of genus 
Roseburia has been associated with chronic inflammation which is also characteristic of 
CMV infection.  
The observed higher differential abundance of genera Prevotella, Lactococcus and 
Exiguobacterium in cases than in controls further confirms Prevotella association with 
increased cytokine release which leads to increased inflammation (Dillon et al., 2016). This 
observation further emphasises the role of gut bacterial profiles in the characteristic nature 
of CMV infection. High relative abundance of Exiguobacterium in the gut has been 
associated with community acquired pneumonia (Chen et al., 2017). Interestingly, CMV has 
also been implicated in severe viral community acquired pneumonia (Gonçalves et al., 
2018). This suggests the possible interaction of gut bacterial profiles with disease outcomes 
and associated symptoms. Gut bacterial profile also been described to play a role in 
vaccination outcomes, with low relative abundance of short chain fatty acids producing 
bacteria such as Lactobacillus and Roseburia being associated with low vaccine success 
rates (Jamieson, 2015; Zimmermann & Curtis, 2018). 
The observation of a trend towards significance (p=0.059) on estimating beta diversity of 
different genotypes of the rs10499563, a SNP in the IL-6 gene suggests the role of genetics 
in shaping gut bacterial profiles. Presence of the SNP results in lower production of the pro-
inflammatory cytokine IL-6 (Smith et al., 2008). It is important to note that inflammation 
through cytokine production plays an important role in maintaining immune balance (Zhang 
et al., 2008). At the same time, gut microbiota also plays a role in maintaining immunity. It 
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is possible that there is an interplay between host immuno-genetic variants and gut 
microbiota profiles.  
4.2 Conclusions and Future Perspectives 
Routine diagnosis mainly performed by ELISA, particularly in the developing world where 
there is a high HIV burden may not be reliable and results in misdiagnosis and 
underestimation of CMV infection cases. Hence, control of antenatal CMV and prevention 
of cCMV will remain a challenge. Findings from this study suggests that the differential 
outcomes of CMV exposure are multifactorial and hence factors such as host genetics and 
concentration of ART have to be taken into account to identify individuals at a higher risk 
of CMV infection. The multifactorial nature of CMV acquisition in addition to wide host 
cell tropism, presents a huge challenge to both the clinician and the drug developer in 
curbing CMV infection. Vaccination against CMV has been largely unsuccessful. 
Considering the potential role of gut bacterial profiles in CMV vaccination and disease 
outcomes, boosting gut bacterial profiles by SCFA producing bacteria may ameliorate 
vaccination outcomes. 
In as much as CMV has been described to take advantage of compromised immunity, data 
from our study findings, particularly CMV-induced gut dysbiosis suggest that CMV may 
actually contribute to immune dysfunction through the gut associated lymphoid tissue. The 
likelihood of immune associated host genetics in shaping gut bacterial profiles warrants 
further investigation. 
In conclusion, there are various factors associated with susceptibility to CMV infection 
which include host genetics and antiretroviral therapy exposure among HIV infected 
pregnant women. Furthermore, CMV infection has an effect on gut bacterial profiles which 
may result in characteristic CMV infection symptoms such as chronic inflammation. 
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The future direction of the current study is to perform CMV testing as well as growth and 
developmental tests on the infants so as to determine the rate of vertical CMV transmission 
and associated birth outcomes in our cohort. Moreover, there is need to assess the possible 
effects of maternal CMV-induced gut dysbiosis on birth outcomes. 
Limitations of study 
We were only able to determine the CMV infection status during pregnancy hence were not 
able to tell status before onset of pregnancy. This information would have allowed us to 
better explain the relationship between CMV reactivation and the physiological changes 
which occur during pregnancy. However, we were still able to associate CMV status during 
pregnancy with factors such as host genetics and gut bacterial profiles. Africans being the 
cradle of mankind, there could have been a possibility to find novel SNPs associated with 
CMV infection if we had used methods such as whole exome sequencing. However, we did 
not have sufficient funds in our project. Availability of stool samples at different time points 
would have allowed conclusions on the causative effects of CMV infection on gut bacterial 
profiles. In this case, findings can only allow us to associate CMV infection status with gut 
bacterial profiles. Furthermore, stool samples at different time points including a point 
before CMV reactivation would have given a clearer relationship between gut bacterial 







4.3 References (Introduction and Summary Discussion chapters) 
Abedi, E., Kheirandish, M., Sharifi, Z., Samiee, S., Kokhaei, P., Pourpak, Z., & Ashraf, M. 
J. (2017). Quantification of Active and Latent Form of Human Cytomegalovirus Infection 
in Umbilical Cord Blood Donors by Real-Time PCR. International Journal of Organ 
Transplantation Medicine, 8(3), 140–145. 
 
Adland, E., Klenerman, P., Goulder, P., & Matthews, P. C. (2015). Ongoing burden of 
disease and mortality from HIV/CMV coinfection in Africa in the antiretroviral therapy era. 
Frontiers in Microbiology, 6. https://doi.org/10.3389/fmicb.2015.01016 
 
Antona, D., Lepoutre, A., Fonteneau, L., Baudon, C., Halftermeyer-Zhou, F., LE Strat, Y., 
& Lévy-Bruhl, D. (2017). Seroprevalence of cytomegalovirus infection in France in 2010. 
Epidemiology and Infection, 145(7), 1471–1478. 
https://doi.org/10.1017/S0950268817000103 
 
Boehme, K. W., Guerrero, M., & Compton, T. (2006). Human cytomegalovirus envelope 
glycoproteins B and H are necessary for TLR2 activation in permissive cells. Journal of 
Immunology (Baltimore, Md.: 1950), 177(10), 7094–7102. 
https://doi.org/10.4049/jimmunol.177.10.7094 
 
Botos, I., Segal, D. M., & Davies, D. R. (2011). The structural biology of Toll-like 
receptors. Structure (London, England: 1993), 19(4), 447–459. 
https://doi.org/10.1016/j.str.2011.02.004  
 
Britt, W. (2008). Manifestations of human cytomegalovirus infection: Proposed 
mechanisms of acute and chronic disease. Current Topics in Microbiology and 
Immunology, 325, 417–470. https://doi.org/10.1007/978-3-540-77349-8_23 
Cannon, M. J., & Davis, K. F. (2005). Washing our hands of the congenital 
cytomegalovirus disease epidemic. BMC Public Health, 5, 70. https://doi.org/10.1186/1471-
2458-5-70 
 
Cha, T. A., Tom, E., Kemble, G. W., Duke, G. M., Mocarski, E. S., & Spaete, R. R. (1996). 
Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory 
strains. Journal of Virology, 70(1), 78–83. 
 
Chacko, B., & John, G. T. (2012). Leflunomide for cytomegalovirus: Bench to bedside. 
Transplant Infectious Disease: An Official Journal of the Transplantation Society, 14(2), 
111–120. https://doi.org/10.1111/j.1399-3062.2011.00682.x 
 
Chee, M. S., Bankier, A. T., Beck, S., Bohni, R., Brown, C. M., Cerny, R., … Barrell, B. G. 
(1990). Analysis of the Protein-Coding Content of the Sequence of Human 
 102 
Cytomegalovirus Strain AD169. In J. K. McDougall (Ed.), Cytomegaloviruses (pp. 125–
169). Springer Berlin Heidelberg. 
 
Cheeran, M. C.-J., Lokensgard, J. R., & Schleiss, M. R. (2009). Neuropathogenesis of 
congenital cytomegalovirus infection: Disease mechanisms and prospects for intervention. 
Clinical Microbiology Reviews, 22(1), 99–126, Table of Contents. 
https://doi.org/10.1128/CMR.00023-08 
 
Chen, D. H., Jiang, H., Lee, M., Liu, F., & Zhou, Z. H. (1999). Three-dimensional 
visualization of tegument/capsid interactions in the intact human cytomegalovirus. 
Virology, 260(1), 10–16. https://doi.org/10.1006/viro.1999.9791 
 
Chen, X., Wang, L., Zhou, J., Wu, H., Li, D., Cui, Y., & Lu, B. (2017). Exiguobacterium 
sp. A1b/GX59 isolated from a patient with community-acquired pneumonia and bacteremia: 
Genomic characterization and literature review. BMC Infectious Diseases, 17. 
https://doi.org/10.1186/s12879-017-2616-1 
 
Compton, T., & Feire, A. (2007). Early events in human cytomegalovirus infection. In A. 
Arvin, G. Campadelli-Fiume, E. Mocarski, P. S. Moore, B. Roizman, R. Whitley, & K. 
Yamanishi (Eds.), Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. 
Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK47369/ 
 
Compton, T., Kurt-Jones, E. A., Boehme, K. W., Belko, J., Latz, E., Golenbock, D. T., & 
Finberg, R. W. (2003). Human Cytomegalovirus Activates Inflammatory Cytokine 
Responses via CD14 and Toll-Like Receptor 2. Journal of Virology, 77(8), 4588–4596. 
https://doi.org/10.1128/JVI.77.8.4588-4596.2003 
 
Cope, A. V., Sweny, P., Sabin, C., Rees, L., Griffiths, P. D., & Emery, V. C. (1997). 
Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after 
renal transplantation. Journal of Medical Virology, 52(2), 200–205. 
 
Crough, T., & Khanna, R. (2009). Immunobiology of Human Cytomegalovirus: From 
Bench to Bedside. Clinical Microbiology Reviews, 22(1), 76–98. 
https://doi.org/10.1128/CMR.00034-08 
 
Dillon, S. M., Lee, E. J., Kotter, C. V., Austin, G. L., Gianella, S., Siewe, B., … Wilson, C. 
C. (2016). Gut dendritic cell activation links an altered colonic microbiome to mucosal and 
systemic T-cell activation in untreated HIV-1 infection. Mucosal Immunology, 9(1), 24–37. 
https://doi.org/10.1038/mi.2015.33 
 
Dollard, S. C., Grosse, S. D., & Ross, D. S. (2007). New estimates of the prevalence of 
neurological and sensory sequelae and mortality associated with congenital 




Emery, V. C. (2001). Investigation of CMV disease in immunocompromised patients. 
Journal of Clinical Pathology, 54(2), 84–88. https://doi.org/10.1136/jcp.54.2.84 
 
Faqi, A. S., Klug, A., Merker, H. J., & Chahoud, I. (1997). Ganciclovir induces 
reproductive hazards in male rats after short-term exposure. Human & Experimental 
Toxicology, 16(9), 505–511. https://doi.org/10.1177/096032719701600905 
 
Feng, X., Schröer, J., Yu, D., & Shenk, T. (2006). Human cytomegalovirus pUS24 is a 
virion protein that functions very early in the replication cycle. Journal of Virology, 80(17), 
8371–8378. https://doi.org/10.1128/JVI.00399-06 
 
Fields, B. N., Knipe, D. M., & Howley, P. M. (2007). Fields virology. Philadelphia: Wolters 
Kluwer Health/Lippincott Williams & Wilkins. 
 
Foolad, F., Aitken, S. L., & Chemaly, R. F. (2018). Letermovir for the prevention of 
cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell 
transplant recipients. Expert Review of Clinical Pharmacology, 11(10), 931–941. 
https://doi.org/10.1080/17512433.2018.1500897 
 
Forbes, B. A. (1989). Acquisition of cytomegalovirus infection: An update. Clinical 
Microbiology Reviews, 2(2), 204–216. https://doi.org/10.1128/CMR.2.2.204 
 
Fortunato, E. A., & Spector, D. H. (1999). Regulation of Human Cytomegalovirus Gene 
Expression. In K. Maramorosch, F. A. Murphy, & A. J. Shatkin (Eds.), Advances in Virus 
Research (Vol. 54, pp. 61–128). https://doi.org/10.1016/S0065-3527(08)60366-8 
 
Francis, S. S., Wallace, A. D., Wendt, G. A., Li, L., Liu, F., Riley, L. W., … Wiemels, J. L. 
(2017). In utero cytomegalovirus infection and development of childhood acute 
lymphoblastic leukemia. Blood, 129(12), 1680–1684. https://doi.org/10.1182/blood-2016-
07-723148 
 
Freitas, V. R., Smee, D. F., Chernow, M., Boehme, R., & Matthews, T. R. (1985). Activity 
of 9-(1,3-dihydroxy-2-propoxymethyl) guanine compared with that of acyclovir against 
human, monkey, and rodent cytomegaloviruses. Antimicrobial Agents and Chemotherapy, 
28(2), 240–245. https://doi.org/10.1128/aac.28.2.240 
 
Gerna, G., Sarasini, A., Patrone, M., Percivalle, E., Fiorina, L., Campanini, G., … Revello, 
M. G. (2008). Human cytomegalovirus serum neutralizing antibodies block virus infection 
of endothelial/epithelial cells, but not fibroblasts, early during primary infection. The 
Journal of General Virology, 89(Pt 4), 853–865. https://doi.org/10.1099/vir.0.83523-0 
 
Gibson, W. (2008). Structure and formation of the cytomegalovirus virion. Current Topics 
in Microbiology and Immunology, 325, 187–204. 
 104 
 
Gonçalves, C., Cipriano, A., Videira Santos, F., Abreu, M., Méndez, J., & Sarmento e 
Castro, R. (2018). Cytomegalovirus acute infection with pulmonary involvement in an 
immunocompetent patient. IDCases, 14, e00445. https://doi.org/10.1016/j.idcr.2018.e00445 
 
Griffiths, P., Baraniak, I., & Reeves, M. (2015). The pathogenesis of human 
cytomegalovirus. The Journal of Pathology, 235(2), 288–297. 
https://doi.org/10.1002/path.4437 
 
Hanley, P. J., & Bollard, C. M. (2014). Controlling Cytomegalovirus: Helping the Immune 
System Take the Lead. Viruses, 6(6), 2242–2258. https://doi.org/10.3390/v6062242 
 
Hertoghs, K. M. L., Moerland, P. D., van Stijn, A., Remmerswaal, E. B. M., Yong, S. L., 
van de Berg, P. J. E. J., … van Lier, R. A. W. (2010). Molecular profiling of 
cytomegalovirus-induced human CD8+ T cell differentiation. The Journal of Clinical 
Investigation, 120(11), 4077–4090. https://doi.org/10.1172/JCI42758 
 
Human Cytomegalovirus (HCMV) | British Society for Immunology. 
https://www.immunology.org/public-information/bitesized-immunology/pathogens-and-
disease/human-cytomegalovirus-hcmv. Accessed 1 May 2019 
 
Humar, A., Kumar, D., Boivin, G., & Caliendo, A. M. (2002). Cytomegalovirus (CMV) 
virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV 
disease. The Journal of Infectious Diseases, 186(6), 829–833. 
https://doi.org/10.1086/342601 
 
Itell, H. L., Nelson, C. S., Martinez, D. R., & Permar, S. R. (2017). Maternal immune 
correlates of protection against placental transmission of cytomegalovirus. Placenta, 60 
Suppl 1, S73–S79. https://doi.org/10.1016/j.placenta.2017.04.011 
 
Jackson, S. E., Mason, G. M., & Wills, M. R. (2011). Human cytomegalovirus immunity 
and immune evasion. Virus Research, 157(2), 151–160. 
https://doi.org/10.1016/j.virusres.2010.10.031 
 
Jamieson, A. M. (2015). Influence of the microbiome on response to vaccination. Human 
Vaccines & Immunotherapeutics, 11(9), 2329–2331. 
https://doi.org/10.1080/21645515.2015.1022699 
 
Jouan, M., Savès, M., Tubiana, R., Carcelain, G., Cassoux, N., Aubron-Olivier, C., … 
Team, for the R. study. (2001). Discontinuation of maintenance therapy for 
cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral 
therapy. AIDS, 15(1), 23. 
 
 105 
Kenneson, A., & Cannon, M. J. (2007). Review and meta-analysis of the epidemiology of 
congenital cytomegalovirus (CMV) infection. Reviews in Medical Virology, 17(4), 253–
276. https://doi.org/10.1002/rmv.535 
 
Khalil, A., Jones, C., & Ville, Y. (2017). Congenital cytomegalovirus infection: 
Management update. Current Opinion in Infectious Diseases, 30(3), 274–280. 
https://doi.org/10.1097/QCO.0000000000000368 
 
Kimberlin, D. W., Jester, P. M., Sánchez, P. J., Ahmed, A., Arav-Boger, R., Michaels, M. 
G., … National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study 
Group. (2015). Valganciclovir for symptomatic congenital cytomegalovirus disease. The 
New England Journal of Medicine, 372(10), 933–943. 
https://doi.org/10.1056/NEJMoa1404599 
 
Klemola, E., Von Essen, R., Henle, G., & Henle, W. (1970). Infectious-mononucleosis-like 
disease with negative heterophil agglutination test. Clinical features in relation to Epstein-
Barr virus and cytomegalovirus antibodies. The Journal of Infectious Diseases, 121(6), 
608–614. https://doi.org/10.1093/infdis/121.6.608 
 
Kogut, M. H., Chiang, H.-I., Swaggerty, C. L., Pevzner, I. Y., & Zhou, H. (2012). Gene 
Expression Analysis of Toll-Like Receptor Pathways in Heterophils from Genetic Chicken 
Lines that Differ in Their Susceptibility to Salmonella enteritidis. Frontiers in Genetics, 3. 
https://doi.org/10.3389/fgene.2012.00121 
 
La Rosa, C., & Diamond, D. J. (2012). The immune response to human CMV. Future 
Virology, 7(3), 279–293. https://doi.org/10.2217/fvl.12.8 
 
Lantos, P. M., Permar, S. R., Hoffman, K., & Swamy, G. K. (2015). The Excess Burden of 
Cytomegalovirus in African American Communities: A Geospatial Analysis. Open Forum 
Infectious Diseases, 2(4), ofv180. https://doi.org/10.1093/ofid/ofv180 
 
Lanzieri, T. M., Chung, W., Flores, M., Blum, P., Caviness, A. C., Bialek, S. R., … 
Congenital Cytomegalovirus Longitudinal Study Group. (2017). Hearing Loss in Children 
with Asymptomatic Congenital Cytomegalovirus Infection. Pediatrics, 139(3). 
https://doi.org/10.1542/peds.2016-2610 
 
Lanzieri, T. M., Dollard, S. C., Bialek, S. R., & Grosse, S. D. (2014). Systematic review of 
the birth prevalence of congenital cytomegalovirus infection in developing countries. 
International Journal of Infectious Diseases: IJID: Official Publication of the International 
Society for Infectious Diseases, 22, 44–48. https://doi.org/10.1016/j.ijid.2013.12.010 
 
Lawrence, G. M., Friedlander, Y., Calderon-Margalit, R., Enquobahrie, D. A., Huang, J. Y., 
Tracy, R. P., … Hochner, H. (2017). Associations of social environment, socioeconomic 
position and social mobility with immune response in young adults: The Jerusalem 
 106 
Perinatal Family Follow-Up Study. BMJ Open, 7(12), e016949. 
https://doi.org/10.1136/bmjopen-2017-016949 
 
Macagno, A., Bernasconi, N. L., Vanzetta, F., Dander, E., Sarasini, A., Revello, M. G., … 
Lanzavecchia, A. (2010). Isolation of human monoclonal antibodies that potently neutralize 
human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-
131A complex. Journal of Virology, 84(2), 1005–1013. https://doi.org/10.1128/JVI.01809-
09 
 
Maidji, E., Somsouk, M., Rivera, J. M., Hunt, P. W., & Stoddart, C. A. (2017). Replication 
of CMV in the gut of HIV-infected individuals and epithelial barrier dysfunction. PLoS 
Pathogens, 13(2). https://doi.org/10.1371/journal.ppat.1006202 
 
Manicklal, S., Emery, V. C., Lazzarotto, T., Boppana, S. B., & Gupta, R. K. (2013). The 
“silent” global burden of congenital cytomegalovirus. Clinical Microbiology Reviews, 
26(1), 86–102. https://doi.org/10.1128/CMR.00062-12 
 
Martin, J. C., Dvorak, C. A., Smee, D. F., Matthews, T. R., & Verheyden, J. P. (1983). 9-
1,3-Dihydroxy-2-propoxymethylguanine: A new potent and selective antiherpes agent. 
Journal of Medicinal Chemistry, 26(5), 759–761. https://doi.org/10.1021/jm00359a023 
 
McBride, J. M., Sheinson, D., Jiang, J., Lewin-Koh, N., Werner, B. G., Chow, J. K. L., … 
Snydman, D. R. (2019). Correlation of Cytomegalovirus (CMV) Disease Severity and 
Mortality with CMV Viral Burden in CMV-Seropositive Donor and CMV-Seronegative 
Solid Organ Transplant Recipients. Open Forum Infectious Diseases, 6(2). 
https://doi.org/10.1093/ofid/ofz003 
 
McGeoch, D. J., Cook, S., Dolan, A., Jamieson, F. E., & Telford, E. A. (1995). Molecular 
phylogeny and evolutionary timescale for the family of mammalian herpesviruses. Journal 
of Molecular Biology, 247(3), 443–458. https://doi.org/10.1006/jmbi.1995.0152 
 
Medicine, I. of. (1999). Vaccines for the 21st Century: A Tool for Decision making. 
https://doi.org/10.17226/5501 
 
Mussi-Pinhata, M. M., Yamamoto, A. Y., Aragon, D. C., Duarte, G., Fowler, K. B., 
Boppana, S., & Britt, W. J. (2018). Seroconversion for Cytomegalovirus Infection During 
Pregnancy and Fetal Infection in a Highly Seropositive Population: “The BraCHS Study.” 
The Journal of Infectious Diseases, 218(8), 1200–1204. 
https://doi.org/10.1093/infdis/jiy321 
 
Mussi-Pinhata, M. M., Yamamoto, A. Y., Moura Brito, R. M., de Lima Isaac, M., de 
Carvalho e Oliveira, P. F., Boppana, S., & Britt, W. J. (2009). Birth prevalence and natural 
history of congenital cytomegalovirus infection in a highly seroimmune population. Clinical 
 107 
Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 
49(4), 522–528. https://doi.org/10.1086/600882 
 
Nigro, G., Adler, S. P., Parruti, G., Anceschi, M. M., Coclite, E., Pezone, I., & Di Renzo, G. 
C. (2012). Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first 
half of pregnancy—A case-control study of the outcome in children. The Journal of 
Infectious Diseases, 205(2), 215–227. https://doi.org/10.1093/infdis/jir718 
 
Noriega, V., Redmann, V., Gardner, T., & Tortorella, D. (2012). Diverse immune evasion 
strategies by human cytomegalovirus. Immunologic Research, 54(1–3), 140–151. 
https://doi.org/10.1007/s12026-012-8304-8 
 
Numazaki, K., Chiba, S., & Asanuma, H. (2001). Transmission of cytomegalovirus. The 
Lancet, 357(9270), 1799–1800. https://doi.org/10.1016/S0140-6736(00)04913-8 
 
Pass, R. F., & Anderson, B. (2014). Mother-to-Child Transmission of Cytomegalovirus and 
Prevention of Congenital Infection. Journal of the Pediatric Infectious Diseases Society, 3 
Suppl 1, S2-6. https://doi.org/10.1093/jpids/piu069 
 
Pass, R. F., Zhang, C., Evans, A., Simpson, T., Andrews, W., Huang, M.-L., … Cloud, G. 
(2009). Vaccine prevention of maternal cytomegalovirus infection. The New England 
Journal of Medicine, 360(12), 1191–1199. https://doi.org/10.1056/NEJMoa0804749 
 
Perucca, E., Ruprah, M., & Richens, A. (1981). Altered drug binding to serum proteins in 
pregnant women: Therapeutic relevance. Journal of the Royal Society of Medicine, 74(6), 
422–426. https://doi.org/10.1177/014107688107400606 
 
Plotkin, S. A., Higgins, R., Kurtz, J. B., Morris, P. J., Campbell, D. A., Shope, T. C., … 
Dankner, W. M. (1994). Multicenter trial of Towne strain attenuated virus vaccine in 
seronegative renal transplant recipients. Transplantation, 58(11), 1176–1178. 
 
Poole, E., Wills, M., & Sinclair, J. (2014). Human Cytomegalovirus Latency: Targeting 
Differences in the Latently Infected Cell with a View to Clearing Latent Infection [Research 
article]. https://doi.org/10.1155/2014/313761 
 
Powers, C., DeFilippis, V., Malouli, D., & Früh, K. (2008). Cytomegalovirus immune 
evasion. Current Topics in Microbiology and Immunology, 325, 333–359. 
 
Prakash, S., & Agrawal, S. (2016). Significance of Pharmacogenetics and 
Pharmacogenomics Research in Current Medical Practice. Current Drug Metabolism, 17(9), 
862–876. https://doi.org/10.2174/1389200217666160804150959 
 
Rawlinson, W. D., Boppana, S. B., Fowler, K. B., Kimberlin, D. W., Lazzarotto, T., Alain, 
S., … van Zuylen, W. J. (2017). Congenital cytomegalovirus infection in pregnancy and the 
 108 
neonate: Consensus recommendations for prevention, diagnosis, and therapy. The Lancet. 
Infectious Diseases, 17(6), e177–e188. https://doi.org/10.1016/S1473-3099(17)30143-3 
 
Regoes, R. R., Frances Bowen, E., Cope, A. V., Gor, D., Hassan-Walker, A. F., Grant 
Prentice, H., … Emery, V. C. (2006). Modelling cytomegalovirus replication patterns in the 
human host: Factors important for pathogenesis. Proceedings of the Royal Society B: 
Biological Sciences, 273(1596), 1961–1967. https://doi.org/10.1098/rspb.2006.3506 
 
Revello, M. G., Lazzarotto, T., Guerra, B., Spinillo, A., Ferrazzi, E., Kustermann, A., … 
Gerna, G. (2014). A Randomized Trial of Hyperimmune Globulin to Prevent Congenital 
Cytomegalovirus. New England Journal of Medicine, 370(14), 1316–1326. 
https://doi.org/10.1056/NEJMoa1310214 
 
Riley, H. D. (1997). History of the cytomegalovirus. Southern Medical Journal, 90(2), 184–
190. https://doi.org/10.1097/00007611-199702000-00004 
 
Rook, A. H. (1988). Interactions of cytomegalovirus with the human immune system. 
Reviews of Infectious Diseases, 10 Suppl 3, S460-467. 
 
Ross, S. A., Novak, Z., Pati, S., & Boppana, S. B. (2011). Overview of the diagnosis of 
cytomegalovirus infection. Infectious Disorders Drug Targets, 11(5), 466–474. 
 
Ross, Shannon A., Ahmed, A., Palmer, A. L., Michaels, M. G., Sánchez, P. J., Bernstein, D. 
I., … Boppana, S. B. (2014). Detection of Congenital Cytomegalovirus Infection by Real-
Time Polymerase Chain Reaction Analysis of Saliva or Urine Specimens. The Journal of 
Infectious Diseases, 210(9), 1415–1418. https://doi.org/10.1093/infdis/jiu263 
 
Ryckman, B. J., Jarvis, M. A., Drummond, D. D., Nelson, J. A., & Johnson, D. C. (2006). 
Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 
to UL150 and occurs by endocytosis and low-pH fusion. Journal of Virology, 80(2), 710–
722. https://doi.org/10.1128/JVI.80.2.710-722.2006 
 
Shenk TE, Stinski MF. Human Cytomegalovirus. Springer Science & Business Media; 
2008. 477 p. 
 
Sinzger, C., Digel, M., & Jahn, G. (2008). Cytomegalovirus Cell Tropism. In T. E. Shenk & 
M. F. Stinski (Eds.), Human Cytomegalovirus (pp. 63–83). https://doi.org/10.1007/978-3-
540-77349-8_4 
 
Sinzger, C., & Jahn, G. (1996). Human cytomegalovirus cell tropism and pathogenesis. 
Intervirology, 39(5–6), 302–319. https://doi.org/10.1159/000150502 
 
Smith, A. J. P., D’Aiuto, F., Palmen, J., Cooper, J. A., Samuel, J., Thompson, S., … 
Humphries, S. E. (2008). Association of serum interleukin-6 concentration with a functional 
 109 
IL6 -6331T>C polymorphism. Clinical Chemistry, 54(5), 841–850. 
https://doi.org/10.1373/clinchem.2007.098608 
 
Steininger, C. (2007). Novel therapies for cytomegalovirus disease. Recent Patents on Anti-
Infective Drug Discovery, 2(1), 53–72. 
 
Stern-Ginossar, N., Weisburd, B., Michalski, A., Le, V. T. K., Hein, M. Y., Huang, S.-X., 
… Weissman, J. S. (2012). Decoding human cytomegalovirus. Science (New York, N.Y.), 
338(6110), 1088–1093. https://doi.org/10.1126/science.1227919 
 
Sylwester, A. W., Mitchell, B. L., Edgar, J. B., Taormina, C., Pelte, C., Ruchti, F., … 
Picker, L. J. (2005). Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T 
cells dominate the memory compartments of exposed subjects. The Journal of Experimental 
Medicine, 202(5), 673–685. https://doi.org/10.1084/jem.20050882 
 
Tan, B. H. (2014). Cytomegalovirus Treatment. Current Treatment Options in Infectious 
Diseases, 6(3), 256–270. https://doi.org/10.1007/s40506-014-0021-5 
 
The University of Chicago. Cytomegalovirus 
(CMV). https://pedclerk.bsd.uchicago.edu/page/cytomegalovirus-cmv (accessed 15 
November 2019)  
 
Tomtishen III, J. P. (2012). Human cytomegalovirus tegument proteins (pp65, pp71, pp150, 
pp28). Virology Journal, 9(1), 22. https://doi.org/10.1186/1743-422X-9-22 
 
Tortorella, D., Gewurz, B. E., Furman, M. H., Schust, D. J., & Ploegh, H. L. (2000). Viral 
subversion of the immune system. Annual Review of Immunology, 18, 861–926. 
https://doi.org/10.1146/annurev.immunol.18.1.861 
 
Vanarsdall, A. L., & Johnson, D. C. (2012). Human cytomegalovirus entry into cells. 
Current Opinion in Virology, 2(1). https://doi.org/10.1016/j.coviro.2012.01.001 
 
Varnum, S. M., Streblow, D. N., Monroe, M. E., Smith, P., Auberry, K. J., Pasa-Tolic, L., 
… Nelson, J. A. (2004). Identification of proteins in human cytomegalovirus (HCMV) 
particles: The HCMV proteome. Journal of Virology, 78(20), 10960–10966. 
https://doi.org/10.1128/JVI.78.20.10960-10966.2004 
 
Verghese, P. S., & Schleiss, M. R. (2013). Letermovir Treatment of Human 
Cytomegalovirus Infection Antiinfective Agent. Drugs of the Future, 38(5), 291–298. 
 
Wang, C., Zhang, X., Bialek, S., & Cannon, M. J. (2011). Attribution of congenital 
cytomegalovirus infection to primary versus non-primary maternal infection. Clinical 
Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 
52(2), e11-13. https://doi.org/10.1093/cid/ciq085 
 110 
 
Wilson, E. M. P., & Sereti, I. (2013). Immune restoration after antiretroviral therapy: The 
pitfalls of hasty or incomplete repairs. Immunological Reviews, 254(1), 343–354. 
https://doi.org/10.1111/imr.12064 
 
Yu, Q., Yuan, L., Deng, J., & Yang, Q. (2015). Lactobacillus protects the integrity of 
intestinal epithelial barrier damaged by pathogenic bacteria. Frontiers in Cellular and 
Infection Microbiology, 5. https://doi.org/10.3389/fcimb.2015.00026 
 
Zimmermann, P., & Curtis, N. (2018). The influence of the intestinal microbiome on 
vaccine responses. Vaccine, 36(30), 4433–4439. 
https://doi.org/10.1016/j.vaccine.2018.04.066 
 
Zhang, J.-P., Li, F., Yu, X.-W., Sheng, Q., Shi, X.-W., & Zhang, X.-W. (2008). Trace 
Elements and Cytokine Profile in Cytomegalovirus-Infected Pregnancies: A Controlled 
Study. Gynecologic and Obstetric Investigation, 65(2), 128–132. 
https://doi.org/10.1159/000110013 
 
Zuhair, M., Smit, G. S. A., Wallis, G., Jabbar, F., Smith, C., Devleesschauwer, B., & 
Griffiths, P. (2019). Estimation of the worldwide seroprevalence of cytomegalovirus: A 




















Appendix B: Ethical clearance from the University of Cape Town Human Research Ethics 
Committee 
Signature removed avoid exposure online
113 
Appendix C: Ethical clearance from the Medical Research Council of Zimbabwe  
Signature removed
 114 




















Appendix E: Additional table for section 3.3.1 
Additional Table 1 Genotype frequencies and univariate logistic regression of SNP with CMV infection status 
SNP Genotype overall CMV+ n (%) CMV- n (%) p-value Codominant OR (95%CI) p-value Log additive OR p-value
TLR2 rs4696480 T/T 50 (45.4) 14 (38.9) 36 (48.6) 0.295 1.00 0.315 
T/A 53 (48.2) 18 (50.0) 35 (47.3) 1.32 (0.57-3.06) 
A/A 7 (6.4) 4 (11.1) 3 (4.0) 3.43 (0.68-17.31) 1.58 (0.82-3.06) 0.172 
TLR2 rs3804099 C/C 54 (49.1) 18 (50.0) 36 (48.6) 0.688 1.00 0.658 
C/T 50 (45.4) 17 (47.2) 33 (44.6) 1.03 (0.46-2.33) 
T/T 6 (5.4) 1 (2.8) 5 (6.8) 0.40 (0.04-3.68) 0.86 (0.44-1.69) 0.659 
TLR2 rs1816702 C/C 25 (22.7) 17 (47.2) 8 (10.8) <0.001 1.00 <0.001 
C/T 64 (58.2) 15 (41.7) 49 (66.2) 0.14 (0.05-0.40) 
T/T 21 (19.1) 4 (11.1) 17 (23.0) 0.11 (0.03-0.44) 0.27 (0.13-0.57) <0.001 
TLR4 rs1554973 C/C 72 (65.4) 25 (69.4) 47 (63.5) 0.568 1.00 0.564 
C/T 31 (28.2) 8 (22.2) 23 (31.1) 0.65 (0.26-1.67) 
T/T 7 (6.4) 3 (8.3) 4 (5.4) 1.41 (0.29-6.80) 0.92 (0.47-1.79) 0.807 
TLR4 rs6478317 G/G 82 (74.5) 27 (75.0) 55 (74.3) 0.853 1.00 0.860 
G/A 26 (23.6) 8 (22.2) 18 (24.3) 0.91 (0.35-2.34) 
A/A 2 (1.8) 1 (2.8) 1 (1.3) 2.04 (0.12-33.83) 1.03 (0.46-2.34) 0.939 
TLR4 rs10759932 T/T 69 (62.7) 22 (61.1) 47 (63.5) 0.740 1.00 0.888 
T/C 40 (36.4) 14 (38.9) 26 (35.1) 1.15 (0.50-2.62) 
C/C 1 (0.9) 0 1 (1.3) - 1.04 (0.47-2.29) 0.888 
TLR4 rs7856729 G/G 41 (37.3) 15 (41.7) 26 (35.1) 0.633 1.00 0.632 
G/T 53 (48.2) 15 (41.7) 38 (51.3) 0.68 (0.29-1.64) 
T/T 16 (14.5) 6 (16.7) 10 (13.5) 1.04 (0.31-3.44) 0.93 (0.52-1.67) 0.807 
TLR7 rs179008 A/A 71 (64.5) 17 (47.2) 54 (73.0) <0.001 1.00 <0.001 
A/T 26 (23.6) 8 (22.2) 18 (24.3) 1.41 (0.52-3.82) 
T/T 13 (11.8) 11 (30.6) 2 (2.7) 17.47 (3.52-86.72) 2.97 (1.63-5.43) <0.001 
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HWE (p-value) 0.0009 0.001 0.652      
TLR9 rs352139 T/T 34 (32.1) 5 (13.9) 29 (41.4) 0.007 1.00 0.005   
T/C 54 (50.9) 21 (58.3) 33 (47.1)  3.69 (1.23-11.04)    
C/C 18 (17.0) 10 (27.8) 8 (11.4)  7.25 (1.92-27.37)  2.70 (1.41-5.17) 0.001 
TLR9 rs5743836 A/A 43 (40.6) 13 (39.4) 30 (41.1) 0.830 1.00 0.835   
A/G 50 (47.2) 15 (45.5) 35 (47.9)  0.99 (0.41-2.40)    
G/G 13 (12.3) 5 (15.1) 8 (11.0)  1.44 (0.40-5.26)  1.14 (0.62-2.10) 0.675 
TLR9 rs187084 A/A 54 (49.5) 18 (50.0) 36 (49.3) 0.638 1.00 0.616   
A/G 45 (41.3) 16 (44.4) 29 (39.7)  1.10 (0.48-2.54)    
G/G 10 (9.2) 2 (5.6) 8 (11.0)  0.50 (0.10-2.60)  0.86 (0.46-1.61) 0.645 
TLR9 rs352140    C/C 48 (43.6) 17 (47.2) 31 (41.9) 0.788 1.00 0.788   
C/T 54 (49.1) 16 (44.4) 38 (51.3)  0.77 (0.33-1.76)    
T/T 8 (7.3) 3 (8.3) 5 (6.8)  1.09 (0.23-5.15)  0.90 (0.47-1.74) 0.763 
IL-6 rs10499563 T/T 47 (43.1) 29 (80.6) 18 (24.7) <0.001 1.00 <0.001   
T/C 56 (51.4) 5 (13.9) 51 (69.9)  0.06 (0.02-0.18)    
C/C 6 (5.5) 2 (5.6) 4 (5.5)  0.31 (0.05-1.87)  0.13 (0.06-0.33) <0.001 
IL-6R rs4537545 T/T 63 (57.3) 23 (63.9) 40 (54.0) 0.399 1.00 0.390   
T/C 37 (33.6) 9 (25.0) 28 (37.8)  0.56 (0.23-1.39)    
C/C 10 (9.1) 4 (11.1) 6 (8.1)  1.16 (0.30-4.54)  0.85 (0.46-1.58) 0.607 
IL-10 rs1800872 G/G 38 (34.5) 11 (30.6) 27 (36.5) 0.825 1.00 0.823   
G/T 58 (52.7) 20 (55.6) 38 (51.3)  1.29 (0.53-3.13)    
T/T 14 (12.7) 5 (13.9) 9 (12.2)  1.36 (0.37-5.00)  1.20 (0.65-2.20) 0.564 
IL-10 rs1878672 G/G 60 (54.5) 22 (61.1) 38 (51.3) 0.515 1.00 0.494   
G/C 44 (40.0) 13 (36.1) 31 (41.9)  0.72 (0.31-1.67)    
C/C 6 (5.4) 1 (2.8) 5 (6.8)  0.35 (0.04-3.15)  0.67 (0.33-1.35) 0.253 
IL-28B rs12979860   T/T 46 (47.9) 16 (50.0) 30 (46.9) 0.948 1.00 0.948   
T/C 32 (33.3) 10 (31.2) 22 (34.4)  0.85 (0.33-2.23)    
C/C 18 (18.7) 6 (18.7) 12 (18.7)  0.94 (0.30-2.97)  0.95 (0.54-1.66) 0.850 
IFNAR1 rs2843710 C/C 8 (15.1) 1 (6.7) 7 (18.4) 0.282 1.00 0.250   
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C/G 45 (84.9) 14 (93.3) 31 (81.6)  3.16 (0.35-28.20)  3.16 (0.35-28.20) 0.250 
G/G 0 0 0  -    
IL-1A rs1800587            T/T 46 (45.1) 17 (50.0) 29 (42.6) 0.692 1.00 0.690   
T/C 42 (41.2) 12 (35.3) 30 (44.1)  0.68 (0.28-1.68)    
C/C 14 (13.7) 5 (14.7) 9 (13.2)  0.95 (0.27-3.30)  0.89 (0.49-1.60) 0.688 
 
 
